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Abstract 
 
This thesis begins with a summary of the general management of faecal incontinence and 
constipation. This is followed by a review of the literature to support the use of neuromodulation for 
these conditions. The first study reports the effect of alteration of pulse width and frequency on sacral 
nerve stimulation for constipation. The next study investigates the outcome of transcutaneous 
stimulation of the sacrum for faecal incontinence. The outcome of pudendal nerve stimulation is 
reported for those who have failed to improve with sacral nerve stimulation. Lastly the effect of 
unilateral transcutaneous posterior tibial nerve stimulation is studied and applied to bilateral 
stimulation. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
5 
 
 
Acknowledgements 
 
I would like to thank my supervisors, Miss Carolynne Vaizey and Professor John Nicholls for their 
guidance and support. I would also like to thank Mr Thomas Dudding for help with planning much of 
this thesis. I wish to acknowledge the assistance of Sister Elissa Bradshaw for the conduct and 
recruitment of several of my studies. Mr Anil George made a significant contribution to the study into 
pudendal nerve stimulation. Assistance with statistical analysis was provided by Mr Paul Bassett. 
Financial assistance was provided by the St Mark’s Foundation, Bowel Disease Research Foundation 
and Medtronic Incorporated. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
6 
 
 
Publications and Presentations arising from the thesis 
 
Review articles 
Chapter 2 
Advances in the Surgical Treatment of Faecal Incontinence 
GP Thomas, CJ Vaizey.  
Current Surgery Reports, 2013, March 1 (1) 
 
Chapter 3 
A Review of Posterior Tibial Nerve Stimulation for Faecal Incontinence.  
G P Thomas, T C Dudding, G Rahbour, R J Nicholls, C J Vaizey.  
Colorectal Disease. 2013 May;15(5):519-26 
 
Chapter 4 
Sacral Nerve Stimulation for Constipation.  
G P Thomas, T C Dudding, G Rahbour, R J Nicholls, C J Vaizey.  
British Journal of Surgery, 2013 vol. 100 (2) 174-81 
 
Original Articles 
Chapter 6 
A pilot study of transcutaneous sacral nerve stimulation for faecal incontinence.  
GP Thomas, C Norton, RJ Nicholls, CJ Vaizey.  
Colorectal Disease. 2013 Nov;15(11):1406-9. 
 
Sacral transcutaneous stimulation for faecal incontinence may have a different mechanism of action to 
sacral nerve stimulation.  
GP Thomas, C Norton, RJ Nicholls, CJ Vaizey.  
Colorectal Disease. 2014 Jan;16(1):68-9. 
 
Chapter 7 
A pilot study of chronic pudendal nerve stimulation for faecal incontinence for those who 
have failed sacral nerve stimulation 
GP Thomas, AT George, TC Dudding, RJ Nicholls, CJ Vaizey 
Accepted by Techniques in Coloproctology 
 
7 
 
Chapter 8 
A Pilot Study to Compare Daily with Twice Weekly Transcutaneous Posterior Tibial Nerve 
Stimulation for Faecal Incontinence. 
GP Thomas, TC Dudding, E Bradshaw, RJ Nicholls, CJ Vaizey.  
Colorectal Disease. 2013 Dec;15(12):1504-9 
 
Bilateral transcutaneous posterior tibial nerve stimulation for faecal incontinence 
GP Thomas, TC Dudding, RJ Nicholls, CJ Vaizey.  
Diseases of the Colon and Rectum. 2013 Sep;56(9):1075-9. 
 
Abstracts 
Can the response to posterior tibial nerve stimulation for faecal incontinence predict the response to 
sacral nerve stimulation?  
GP Thomas, TC Dudding, RJ Nicholls, CJ Vaizey. 
Gut. PWE-016. 2013. Jun, 62(Supp1):1-293. 
 
Development of an optimum treatment regimen for transcutaneous posterior tibial nerve stimulation 
for faecal incontinence.  
G P Thomas, T C Dudding, E Bradshaw, R J Nicholls, C J Vaizey.  
Gut. PWE-014. 2013. Jun, 62(Supp1):1-293.   
 
Development of an optimum treatment regimen for transcutaneous posterior tibial nerve stimulation 
for faecal incontinence.  
G P Thomas, T C Dudding, E Bradshaw, R J Nicholls, C J Vaizey. 
Colorectal Disease. Vol 15 (suppl 1), 1-65, 2013 
 
Transcutaneous sacral nerve stimulation for faecal incontinence. 
 GP Thomas, C Norton, RJ Nicholls, CJ Vaizey. 
Gut. OC-088. 2013. Jun, 62(Supp1):1-293. 
 
Transcutaneous sacral nerve stimulation for faecal incontinence. 
GP Thomas, C Norton, RJ Nicholls, CJ Vaizey 
Colorectal Disease. Vol 15 (suppl 1), 1-65, 2013 
 
 Pudendal nerve stimulation in the treatment of faecal incontinence. 
GP Thomas, AT George, TC Dudding, RJ Nicholls, CJ Vaizey  
Colorectal Disease. Vol 15 (suppl 1), 1-65, 2013 
8 
 
Presentations 
Development of an optimum treatment regimen for transcutaneous posterior tibial nerve stimulation 
for faecal incontinence 
G P Thomas, T C Dudding, E Bradshaw, R J Nicholls, C J Vaizey 
Oral presentation at the Royal Society of Medicine 2013. 
 
Development of an optimum treatment regimen for transcutaneous posterior tibial nerve stimulation 
for faecal incontinence 
G P Thomas, T C Dudding, E Bradshaw, R J Nicholls, C J Vaizey 
Oral presentation at the Association of Coloproctology of Great Britain and Ireland 2013. 
 
Development of an optimum treatment regimen for transcutaneous posterior tibial nerve stimulation 
for faecal incontinence 
G P Thomas, T C Dudding, E Bradshaw, R J Nicholls, C J Vaizey 
Poster presentation at the British Society of Gastroenterology 2013. 
 
Development of an optimum treatment regimen for transcutaneous posterior tibial nerve stimulation 
for faecal incontinence 
G P Thomas, T C Dudding, E Bradshaw, R J Nicholls, C J Vaizey 
Poster presentation at the European Society of Coloproctology, Belgrade, 2013. 
 
Transcutaneous sacral nerve stimulation for faecal incontinence 
GP Thomas, C Norton, RJ Nicholls, CJ Vaizey 
Oral presentation at the Association of Coloproctology of Great Britain and Ireland 2013. 
 
Transcutaneous sacral nerve stimulation for faecal incontinence 
GP Thomas, C Norton, RJ Nicholls, CJ Vaizey 
Oral presentation at the British Society of Gastroenterology 2013. 
 
Transcutaneous sacral nerve stimulation for faecal incontinence 
GP Thomas, C Norton, RJ Nicholls, CJ Vaizey 
Oral presentation at the London Surgical Symposium 2013. 
 
Pudendal nerve stimulation in the treatment of faecal incontinence 
GP Thomas, AT George, TC Dudding, RJ Nicholls, CJ Vaizey 
Oral presentation at the European Society of  Coloproctology, Belgrade, 2013 
 
9 
 
Pudendal nerve stimulation in the treatment of faecal incontinence 
GP Thomas, AT George, TC Dudding, RJ Nicholls, CJ Vaizey 
Poster presentation at the Association of Coloproctology of Great Britain and Ireland 2013 
 
Pudendal nerve stimulation in the treatment of faecal incontinence 
GP Thomas, AT George, TC Dudding, RJ Nicholls, CJ Vaizey 
Poster presentation at the British Society of Gastroenterology 2013. 
 
Can the response to posterior tibial nerve stimulation for faecal incontinence predict the response to 
sacral nerve stimulation? 
GP Thomas, TC Dudding, RJ Nicholls, CJ Vaizey 
Poster presentation at the British Society of Gastroenterology 2013. 
 
Factors predictive of success of transcutaneous posterior tibial nerve stimulation for faecal 
incontinence. 
GP Thomas, TC Dudding, RJ Nicholls, CJ Vaizey 
Poster presentation at the European Society of Coloproctology, Belgrade, 2013. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
10 
 
CHAPTER 1 
 
Overall aims and outline of thesis 
 
This thesis aims to investigate different methods of optimising existing neuromodulatory treatments 
for faecal incontinence and constipation. The three forms used most widely have been sacral nerve 
stimulation, posterior tibial nerve stimulation and pudendal nerve stimulation. The research on sacral 
nerve stimulation is described in chapters five and six, pudendal nerve stimulation is described in 
chapter seven and posterior tibial nerve stimulation is described in chapter eight. The aims for each 
chapter are summarised below. 
 
 
CHAPTER 2     
2.1 Overview of the treatment of faecal incontinence  
2.2 Overview of the treatment of constipation 
This chapter provides an overview of the treatment of faecal incontinence and constipation. It 
describes the current position of neuromodulation in the treatment pathway for these conditions.  
 
     
CHAPTER 3  
Neuromodulation for faecal incontinence 
2.1 Sacral nerve stimulation  
2.2 Posterior tibial nerve stimulation  
2.3 Pudendal nerve stimulation  
This chapter reviews the scientific literature on neuromodulation for faecal incontinence. It includes a 
systematic review on the use of posterior tibial nerve stimulation for this condition. 
 
 
CHAPTER 4   
Neuromodulation for constipation 
3.1 Sacral nerve stimulation   
3.2 Posterior tibial nerve stimulation   
3.3 Pudendal nerve stimulation  
This chapter reviews the literature on neuromodulation for constipation. It includes a systematic 
review of the use of sacral nerve stimulation for this condition. 
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CHAPTER 5   
Double blind randomised controlled multicentre study to compare the effect of stimulation parameter 
changes on sacral nerve stimulation for constipation. 
 
Sacral nerve stimulation (SNS) is typically delivered using a fixed pulse width and frequency.  
The amplitude and lead electrode position are variable. These settings are based on historical data 
derived from studies in patients with bladder dysfunction. SNS can be an effective treatment for 
constipation, but even when successful, improvement is usually partial rather than complete. The 
effect of altered pulse width and frequency on SNS for faecal incontinence has been reported. An 
improvement in symptoms was seen when a higher frequency was used. The aim of this study was to 
see if the efficacy of SNS for constipation can be improved by altering these stimulation parameters.  
 
 
CHAPTER 6  
Studies into transcutaneous stimulation over the sacrum for faecal incontinence 
 
Until recently, only one study has reported transcutaneous SNS for faecal incontinence. This 
described unilateral stimulation of the area over the third sacral foramen for two hours a day over 
three months. Encouraging results were seen. Transcutaneous SNS is cheaper and safer than SNS by 
direct electrode stimulation of the anterior nerve root.  
 
The aim of the first study was to see if a more intensive treatment regimen, using bilateral stimulation 
over the entire sacrum, could achieve a significant therapeutic effect.  
 
The next study attempted to see if transcutaneous SNS had a similar mechanism of action to SNS. 
Stimulation of the third sacral nerve root using a SNS electrode causes contraction of the external anal 
sphincter. The aim of the next study was to see if transcutaneous SNS had a similar effect on the 
sphincter. It is unlikely that transcutaneous SNS has a similar mechanism of action to SNS. It may be 
that it is only providing cutaneous stimulation. The final study in this chapter aimed to see whether 
cutaneous electrical stimulation of another area of the body can achieve a similar therapeutic effect. 
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CHAPTER 7  
Pudendal nerve stimulation for faecal incontinence 
 
This chapter describes a pilot study of the medium term outcome of pudendal nerve stimulation for 
faecal incontinence. There are several reports of its use for bladder dysfunction, but except two cases 
reports, this technique has not been reported for faecal incontinence.  
 
 
CHAPTER 8  
Studies of transcutaneous posterior tibial nerve stimulation for faecal incontinence 
 
Posterior tibial nerve stimulation (PTNS) has been reported to be effective for faecal incontinence. 
Many different techniques have been reported. The first study carried out aimed to compare a more 
intensive treatment regimen with the less intensive regimen of unilateral transcutaneous PTNS. The 
second study investigated bilateral transcutaneous PTNS, using the optimal stimulation regimen 
determined from the first study. Bilateral transcutaneous PTNS has not been reported previously. The 
final study used the data from the earlier two studies to see which factors might affect the outcome of 
transcutaneous PTNS. 
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CHAPTER 2 
 
2.1 Overview of the treatment of faecal incontinence 
 
Introduction 
 
Faecal incontinence (FI) is common. It occurs in 2% to 20% of the adult population in the western 
world 
1-4
. It is under reported and most commonly affects women over 65 years of age 
2
.  It causes 
considerable morbidity and reduces quality of life. It may be caused by increased forced of expulsion 
of faeces or by an impaired ability to retain them. The former may be due to inflammation causing 
irritability of the rectum or to loss of rectal or neorectal capacity. Failure to retain faeces may be due 
to motor or sensory impairment of the anorectal sphincter mechanism. In many patients both factors 
are present. The main causes are summarised in Table 1.  
 
Treatment strategy 
 
Conservative treatment should be offered initially. This includes anti-diarrhoeal medication, the use of 
a pad or anal plug, pelvic floor physiotherapy and biofeedback 
5
. A recent Cochrane review of 
biofeedback for FI, found little good quality evidence for its effectiveness. However, the authors 
concluded that biofeedback was probably superior to pelvic floor exercise alone 
6
. Retrograde rectal 
irrigation may be effective in up two thirds of patients 
7
. More invasive treatment is reserved for those 
who fail conservative therapy. Neuromodulatory therapies are described in Chapter 2. An overview of 
the treatment pathway is shown in Figure 1. A full thickness external rectal prolapse should be 
surgically corrected before any other treatment. 
 
a. Injectable anal bulking agents 
 
The first report of an injectable bulking agent to treat faecal incontinence was published in 1993 
8
. 
This used a Teflon-like material. Since then many different materials have been studied. The results 
have generally been disappointing, mostly due to poor efficacy and safety 
9
. The short term results of 
a new bulking agent, the Anal Gatekeeper, have recently been reported 
10
. This consisted of an 
implantable cylinder of polyacrylonitrile, injected into the intersphincteric space. Episodes of passive 
incontinence improved from 7.1 (7.4) per week at baseline to 0.4 (0.6) per week at 33.5 (12.4) months 
mean follow up. Clinical improvement correlated with improved quality of life. No adverse effects 
were reported, but the study was small (n=14). Larger studies are currently under way. 
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a. Radiofrequency ablation (SECCA) 
 
The SECCA system (Curon Medical Inc, Sunnyvale, CA, USA) works by delivering radiofrequency 
energy to the internal anal sphincter to induce fibrosis to cause anal canal closure by contraction of 
collagen. It is used for passive FI in which internal sphincter weakness predominates. It is a day case 
procedure and can be performed under local anaesthesia with sedation. In 2002 Takahsahi et al 
11
 
reported its use in ten patients with idiopathic FI. At six months a significant improvement in the 
Wexner FI score was seen (13.5 to 5). Less impressive improvements in the Wexner FI score were 
reported by Efron in 2003 
12
, Lefebure in 2008 
13
 and Ruiz in 2010 
14
 (14.5 to 11.1, 14.07 to 12.33 and 
15.6 to 12.9 respectively). Most patients remained moderately incontinent after treatment and it 
appears that SECCA gives only a marginal benefit. 
 
b. Anal Sphincteroplasty 
 
Overlapping sphincter repair is the operation of choice for most patients with an external anal 
sphincter defect. In a recent systematic review of the long term outcome of 900 patients at five or 
more years 
15
, the authors found marked differences in the criteria adopted among the studies to define 
incontinence. There was however an initial improvement in most studies followed by a gradual 
deterioration over time. This deterioration did not however, correlate with quality of life or patient 
satisfaction. No consistent predictive factors for failure were identified.  
 
c. Artificial Anal Sphincter prostheses 
 
AMS 800 and Acticon Neosphincter 
The use of an artificial anal sphincter for FI was first reported in 1987 
16
. This utilized the AMS 800 
device, which had originally been devised for urinary incontinence. Many reports have further 
described its efficacy 
17-23
 and subsequently the device being applied to the anus was renamed the 
Acticon neosphincter. The device consists of an inflated cuff which encircles the sphincter complex. 
This is connected to a hydraulic system whereby deflation of the cuff is effected by a pump located in 
the labia majora or scrotum when defecation is desired. A systematic review 
24
 of 14 reports found a 
very high incidence of device removal mostly due to erosion, infection or mechanical failure. Few 
reports analysed the data on an intention to treat basis, but patients who continued to have a 
functioning implant experienced a significant improvement in symptoms. These results were reflected 
by a recent report describing 52 patients, who had been implanted with the Acticon device over a 14 
year period 
25
. At a mean follow up of 64.3 ±46.5 months, 26% had had the device removed owing to 
infection in most cases and 24% underwent revision due to device failure. Of the patients left with a 
15 
 
functioning device, 67.3% had a significant improvement in the Wexner faecal incontinence score and 
in quality of life. 
 
The Prosthetic Anal Sphincter 
The prosthetic anal sphincter (PAS), was reported in 2004 
26
. This expandable device is placed at the 
anorectal junction, and acts to accentuate the effect of puborectalis, by narrowing the angle between 
the rectum and anus. The PAS can be controlled by the patient, to allow the anorectal angle to 
straighten when defecation is desired. In a report of 12 patients at a median follow up of 59 (30-72) 
months, ten became continent. The Wexner faecal incontinence score improved from 16 (7-20) at 
baseline to 3 (0-7). Two devices were removed due to infection following revisional surgery. Despite 
this, the reported improvement in symptoms is encouraging.  
 
The Magnetic Anal Sphincter 
The magnetic anal sphincter is a recent development. It includes a flexible ring of magnetic titanium 
beads which is inserted around the anal canal in a similar manner to its use for gastro-oesophageal 
reflux. The beads come together by magnetism to close the anus and the pressure exerted by voluntary 
defecation separates them to allow defecation. In a preliminary report of 14 patients 
27
, three had the 
device removed and at a median follow up of six months, five of the remaining patients had a 
significant reduction in incontinent episodes from 7.2 at baseline to 0.7 with a significant 
improvement in quality of life. 
 
A small non-randomised study indirectly compared the outcome of the magnetic anal sphincter (n=10) 
with the Acticon device (n=10)
28
. Four of the latter were revised and two were removed owing to 
infection. One of the former spontaneously eroded. Overall a significant reduction in the Wexner 
faecal incontinence score was seen in both groups. Sacral nerve stimulation was compared with the 
magnetic anal sphincter in a similar fashion 
29
. Both therapies achieved a significant reduction in 
episodes of incontinence and improvements in quality of life. In both studies, it is likely that multiple 
reporting of the same patients had taken place. These studies were non-randomised and small, 
therefore it is difficult to draw any firm conclusions. Larger, truly prospective randomised trials are 
needed to determine the efficacy and safety of the magnetic anal sphincter.  
 
 
d. Graciloplasty 
Non-stimulated graciloplasty was first described in 1952 
30
. The gracilis muscle derives its blood 
supply proximally, so can be divided distally without compromising viability. The muscle is 
mobilised to encircle the anus. The results were disappointing initially. Stimulation of the nerve 
supplying the gracilis muscle, dynamic graciloplasty, was described in 1988 
31
. High frequency 
16 
 
stimulation by an implantable pulse generator, converts the fast twitch fibres of the gracilis to fatigue 
resistant slow twitch activity. This has lead to an improved outcome, with up to 60% of patients 
reported to have improved function in some studies 
32
, although others have been less successful 
33
 
The procedure is associated with high complication and reoperation rates with the former occurring in 
up to two thirds of patients 
34
. 
 
e. Antegrade colonic enema 
First reported by Malone in 1990 
35
, this utilised a Mitrofanoff valve to produce a catheterisable 
continent colonic stoma to permit antegrade colonic irrigation. Worsoe and colleagues 
36
 reported 80 
patients who had undergone an antegrade colonic enema, 69 of whom used an appendicostomy. At a 
median follow up of 75 months, 38% had had complications related to the appendicostomy and 
success was reported in 51 (74%). Chereau et al 
37
 reported a similar outcome. Seventy five patients 
underwent this procedure, 68 of whom had an appendicostomy. Complications occurred in 16 (21%). 
At a median follow up of 48 months, 64 were still using the stoma, and of these 55 (86%) had a 
satisfactory outcome with a fall in the Wexner score from 14.3 (±2.9) to 3.4 (±2.4). 
 
 
 
f. Stoma 
When other treatments fail, a stoma may be the best means of management. It can bring relief with 
improved quality of life to a patient for whom other treatments are not adequate. Faecal diversion can 
be either by ileostomy or colostomy. Patients who have a stoma after more conservative failed 
attempts to improve incontinence may be very satisfied with the result 
38
 .  Anal leakage of mucus 
from the rectum may continue to be troublesome however and occasionally it may be necessary to 
perform rectal excision after a stoma for incontinence. Stoma related complications including 
herniation, prolapse and retraction are common particularly in an elderly patient.  
 
 
2.2 Overview of the treatment of constipation 
 
Introduction 
 
It has been estimated that, worldwide, around 14% of adults suffer from constipation. The incidence is 
higher in older patients, in females and in those of lower socioeconomic status 
39
.  Constipation has 
been defined by various consensus groups, such as the Rome Foundation which developed the Rome 
III criteria. According to these, two of six symptoms must be present for 6 months or more. The 
symptoms include straining at stool, passing hard stools, sensation of incomplete emptying, sensation 
17 
 
of anorectal obstruction, self digitation and a defecation frequency of less than three times per week. 
40
. These diagnostic criteria reflect the variety of symptoms that can be present with constipation, 
along with abdominal pain, bloating and frequent laxative and enema use. 
 
The pathogenesis of constipation can be broadly subdivided into disorders of colonic motility and 
evacuatory dysfunction, with a degree of overlap in many patients 
41
. Various factors may be 
responsible for delayed colonic motility, these include immobility, age, medication, endocrine, 
psychological, aganglionosis and pseudo-obstruction. Evacuatory dysfunction may be due to a 
mechanical cause, such as rectal intusussception, rectal prolapse, rectocele or enterocele. It may also 
be due to functional causes such as anismus or dyssynergia, descending perineum syndrome or spinal 
injury. In many patients, both mechanical and functional elements will co-exist. 
 
Treatment 
 
Medical treatment includes dietary advice, drug treatment (laxatives, enemas, suppositories) and 
biofeedback. Chiotakakou-Faliakou and colleagues reported the outcome of 100 patients who had 
undergone biofeedback for constipation. This group included equal proportions of those with slow 
colonic transit and impaired pelvic floor co-ordination. At a median follow up of 23 (12-44) months 
57% felt that their symptoms had improved significantly 
42
. A flow diagram of the treatment for 
constipation is shown in Figure 2. Neuromodulation is usually offered if a patient fails to improve 
following conservative measures. This is discussed in more detail in chapter four. It is helpful in about 
50% of patients selected for this treatment and in these the abdominal symptoms of distension and 
discomfort may also be relieved. 
 
 Surgery has a role in a few carefully selected cases if conservative treatment, including 
neuromodulation, fails and the patient is still severely symptomatic. In those with slow transit 
constipation, an antegrade continence enema procedure (ACE) or colectomy with or without stoma 
formation has been advocated 
41
. While often successful in childhood, the ACE procedure in adults is 
associated with a high complication rate, up to 88% re-operation rate and a 48 - 59% failure rate 
through dropouts in the medium term. Colectomy often improves defecation frequency but symptoms 
of abdominal pain persist in 41% of patients, this perhaps reflects the pan-enteric motility disorder 
that exists in many subjects. Following colectomy, 14% of patients develop diarrhoea and/or faecal 
incontinence and 18% adhesional small bowel obstruction 
43
. 
 
For patients with solely rectal hyposensitivity or pelvic floor dyssynergia, abdominal or perineal 
surgery is not an option. In those with mechanical dysfunction, operations can be divided into 
“hitching” procedures (e.g. rectopexy) or “excision” procedures (e.g. stapled transanal rectal 
18 
 
resection). It should be noted that functional and mechanical deficiencies may often coexist to varying 
degrees. In such patients, correction of the pelvic floor and rectal anatomy may not always improve 
symptoms. The literature in this area is complicated by the heterogenicity in the groups of patients 
studied. Rectal intussusception and rectocele are often observed in patients with normal evacuation 
and the relevance of finding these abnormalities on proctography remains unclear. Reports of 
worsened constipation with posterior rectopexy have swung current treatment algorithms towards 
ventral mesh in rectopexy which is often coupled with colpopexy in women with inadequate support 
of the vaginal vault. STARR remains an alternative treatment option, however there are concerns 
about its potentially significant complications. A defunctioning colostomy is an alternative for these 
patients. A proposed treatment algorithm is shown in figure 2.  
 
Table 1. Summary of the main causes of faecal incontinence 
 
 
Colorectal  disease Anal sphincter weakness 
Inflammatory (enteritis, colitis, proctitis) Intact sphincter  
Functional weakness 
age, neurological disorder, myopathy, 
radiotherapy  
Irritable bowel syndrome Ruptured sphincter 
obstetric, anal surgery, trauma  
Reduced rectal capacity (post rectal resection, 
radiotherapy) 
Rectal fistula to vagina or perineum 
Congenital anomaly Physiological activation of the anorectal 
inhibitory reflex in faecal impaction 
 
 
 
 
 
 
 
 
 
19 
 
Figure 1. Flow Diagram of the treatment pathway for faecal incontinence 
 
 
Faecal incontinence 
 
 
Exclude colorectal pathology  
(Colonoscopy/ CT colonography) 
 
 
Anorectal physiology testing 
Rectal prolapse          Endoanal ultrasonography 
         
    
Abdominal/ perineal repair 
 
 
Dietary advice, anti-diarrhoeal agents, 
 pelvic floor physiotherapy, 
 biofeedback, suppositories, retrograde rectal irrigation 
 
 
Neuromodulation#    Sphincteroplasty* 
 
 
     Neosphincters 
 
 
      Stoma 
 
 
#at present it is uncertain whether sacral nerve stimulation or posterior tibial nerve stimulation should 
be offered first. Pudendal nerve stimulation is not available outside a research setting. 
* only applicable to selected patients. Typically younger patients, with a full length external anal 
sphincter defect and a good level of residual muscle function.  
Sphincter disruption Sphincter ring intact  
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Figure 2. Proposed treatment algorithm for the treatment of constipation 
 
Failed medical and behavioural management 
enemas and rectal irrigation 
 
 
Psychological disorders excluded 
 
 
 
Slow transit constipation                                                                                                                        Evacuation disorder 
 
 
     Rectal hyposensitivity          Mechanical outlet obstruction Pelvic floor dysynergia 
 
SNS                               SNS  Rectocele with   Anorectal  Functionally No surgery  
digitation  intussusception  significant  
and barium trapping    enterocele 
 
 
 
ACE          Rectocele                    VMR  VMR Rotating laxative treatment  
        repair   or STARR  
 
 
 
Ileostomy (Colectomy)     Sigmoid Colostomy 
 
 
 
This algorithm applies to those patients in whom Hirschsprung’s disease and megabowel have been excluded. 
SNS= sacral nerve stimulation; ACE= antegrade colonic enema; STARR= stapled transanal rectal resection; VMR= ventral mesh rectopexy. 
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Chapter 3 
 
Neuromodulation for faecal incontinence 
 
3.1 Sacral nerve stimulation for faecal incontinence 
 
Introduction 
 
Sacral nerve stimulation (SNS) is achieved by direct stimulation of the third sacral nerve root, or, less 
commonly the second or fourth root. It was first developed  for bladder dysfunction in 1982 
44
and was 
applied to faecal incontinence (FI) in 1995 
45
. The effect of SNS was reported in three patients with 
faecal incontinence with encouraging results.  SNS has become increasingly popular and is now 
considered by many to be the first line treatment for patients who have failed to improve with 
conservative treatment. 
 
Method 
 
A review was carried out of publications on sacral nerve stimulation for faecal incontinence. Medline, 
Pubmed and Embase databases were searched electronically using the keywords and/ or MeSH 
“sacral”, “faecal incontinence”, “neuromodulation”, “stimulation”. Further relevant studies were 
identified by cross referencing from relevant articles and abstracts. Only studies that reported the 
clinical outcome of SNS for faecal incontinence in the English language were reviewed. 
 
Description of use 
a. Test stimulation 
Prior to chronic stimulation, the patient must undergo a period of test stimulation. This is typically 
two to three weeks in duration and is known as peripheral nerve evaluation, or PNE. At the end of this 
period the patient’s response to PNE is evaluated. An objective measure of this can be gained by a 
prospectively kept bowel diary. If the patient has achieved a successful response, they may then be 
offered chronic stimulation. A successful response has been judged arbitrarily to be a 50% or more 
improvement in the frequency of incontinent episodes, incontinent days or in the ability to defer 
defecation. 
 
PNE may be performed under local or general anaesthesia. The patient is positioned in the prone 
position. Antibiotics are administered. The buttocks are strapped apart, and the lower back and anal 
area are prepared. Using surface anatomy, a hollow PNE foramen needle is placed percutaneously 
22 
 
into the third posterior sacral foramen. It is then connected to an external stimulation device (Test 
stimulator 3692, Medtronic Inc, Minnesota, USA). Correct needle positioning is confirmed by either a 
sensory response in the anal area, or by contraction of the external anal sphincter and in some 
instances flexion of the ipsilateral hallux. Once the needle is positioned correctly, the PNE lead is fed 
down it, and the needle in the foramen is removed. The PNE lead is secured with adhesive tape and 
connected to the black socket of another lead. The red plug of this lead is connected to a ground pad, 
which is placed on the upper ipsilateral buttock. Further adhesive dressings are placed over the lower 
back so as to cover this area. The lead is connected to the external stimulation device (Test stimulator 
3692, Medtronic Inc, Minnesota, USA). The frequency is set to 14Hz and the pulse width to 
210µsecs. The amplitude is set at level just perceived by the patient or to a level just below this point. 
The patient should experience a tingling sensation in the perianal or natal cleft area at sensory 
threshold. Stimulation is provided continuously throughout the test period. At the end of this time, the 
lead can be removed without the need for anaesthesia. 
 
b. Chronic stimulation 
This may be performed under local or general anaesthesia. The patient is positioned prone. The third 
sacral foramen is entered using a needle electrode in the same manner as during PNE. Once in place, a 
guide wire is inserted down the needle and the electrode is then removed. The skin at the point of 
puncture is opened a little by a number 11 scalpel, and an introducer sheath is passed over the guide 
wire. This is then advanced under X-ray guidance so that its tip comes to be at the level with the 
cortex of the anterior sacral bone. Under radiological control the permanent lead is placed down the 
introducer (Medtronic model 3093).  
 
Satisfactory insertion is achieved if one or two proximal electrodes lie within the third sacral foramen. 
Each electrode is tested to ensure that contraction of the external anal sphincter is achieved, if this is 
performed under local anaesthesia then a sensory response should be sought. The sheath is then 
withdrawn and as it comes out, the barbs of the electrode lead are deployed thereby fixing it in the 
tissues. The pulse generator (Medtronic model 3058) is implanted in a subcutaneous pocket in the 
ipsilateral buttock, at a point away from any pressure area. A site just below belt line is ideal. The 
electrode is tunnelled subcutaneously to the pulse generator and is connected. The wounds are closed 
with sutures. The device is activated once the patient has fully recovered from the anaesthesia. The 
settings can be adjusted by the clinician using a remote control device (Medtronic N’Vision 8840) or 
by the patient (Medtronic iCon 3037). 
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Outcome of SNS for FI 
 
The early reports of SNS for FI all described significant improvements in the frequency of incontinent 
episodes and in the ability to defer defecation. Improvements in quality of life measures were also 
observed 
46-50
. The follow up in these studies was no longer than a median 24 months. The success 
rate of PNE ranged from 80 to 100%. Most reported the outcome of SNS in those with structurally 
intact anal sphincters. The effects of SNS on those with a sphincter lesion are discussed below. A 
systematic review by Jarrett and colleagues in 2004 summarised the early evidence 
51
.  They reported 
the outcome of 266 patients in six published series, including 11 to 116 patients. The follow up ranged 
from one to 99 months. The PNE success rate was between 55 to 80%. Seventy five to 100% of those 
with a permanent implant experienced a 50% or more improvement in the frequency of incontinent 
episodes and 41-75% achieved complete continence. There were also significant improvements in 
symptom severity scores and in quality of life measures. 
 
Larger prospective series have confirmed the effectiveness of SNS. Melenhorst and colleagues 
52
 
reported on 134 patients who underwent PNE, of these 100 (74.6%) went onto chronic stimulation. 
The mean number of incontinent episodes per week fell from 31.3 to 4.4 (p=0.0001) at a mean follow 
up of 25.5 (2.5-63.2) months. Michelsen 
53
 reported the outcome of 177 patients, of whom 142 (80%) 
had a good response to PNE. The median Wexner incontinence score 
54
 improved from 16 (6-20) to 
10 (0-20) (p=0.0001) at a median follow up of 24 (3-72) months. In 2010, Wexner and colleagues 
55
 
described 133 patients who had undergone PNE. 120 had a satisfactory response and underwent 
chronic stimulation. At a follow up of 24 months, 85% had experienced a greater than 50% 
improvement in their symptoms. 
 
The efficacy of SNS over the longer term has now been described. George and colleagues 
summarised the results of SNS over a 10 year period in 2012
56
. Twenty three patients had undergone 
chronic stimulation, of these 12 (52%) had maintained complete continence at a median follow up of 
114 (96-164) months. Two of the 23 had lost efficacy at 48 and 60 months respectively. Hull 
57
 
reported the outcome of 76 patients at a minimum of five year follow up. Sixty four (89%) achieved a 
greater than 50% reduction in incontinent symptoms, and 26 (30%) achieved complete continence. 
Five patients experienced a loss of efficacy by year five.  
 
Comparison against control and other treatments  
 
Two studies have attempted to compare SNS to placebo. Both utilised a double blinded cross over 
design. The first was by Vaizey and colleagues in 2000 
58
. This was a double blinded cross over study. 
Two patients with passive faecal incontinence had undergone nine months of SNS. Each was exposed 
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to a trial period of two two-week periods, with the stimulator turned on for two weeks and off for two 
weeks. There was a large improvement in incontinent episodes per week during the on period when 
compared to the off period with rates of 0 and 2 per week and four and 20 per week, in the on and off 
groups. The second study was by Leroi and colleagues 
59
. Twenty seven patients were randomised to 
one month periods with the stimulator switched on or off. There was a significant improvement in the 
frequency of incontinent episodes per week, in the ability to defer defecation, a disease specific 
quality of life score and in the Wexner score in the on compared with the off group. A recent abstract 
from Giannini and colleagues 
60
 has, however, suggested that simply switching the device off may not 
be an adequate placebo. They reported 18 patients, with faecal and urinary incontinence, who had 
successfully undergone SNS for at least one year. The implants were deactivated and patients were 
followed up to see when the symptoms began to deteriorate.  They did so in 10 patients by four 
months and in the remaining eight by 12 months.   
 
Only one study has attempted prospectively to compare SNS with another established treatment. 
Tjandra 
61
 compared SNS to medical treatment in two randomised matched groups of 60 patients. 
Medical treatment included pelvic floor physiotherapy, stool bulking agents and dietary manipulation. 
They reported no improvement in the control group. However, significant improvements in the 
frequency of incontinent episodes per week, ability to defer defecation and in the Rockwood QOL 
score were seen in the SNS group. Several studies have sought to compare SNS indirectly with other 
treatments, including sphincteroplasty 
62
, the magnetic anal artificial sphincter 
29
 and the artificial 
bowel sphincter [Acticon] 
63
. All have suggested equivalence or superiority of SNS. However, given 
the design of these studies, their conclusions must be viewed with caution. As yet, no published work 
has directly compared SNS to any of these alternative treatments. 
 
Sphincter defect 
 
Leroi and colleagues first reported the effect of SNS in patients with an anal sphincter lesion 
64
. A 
systematic review by Ratto and colleagues 
65
 evaluated the available data concerning SNS for those 
with an anal sphincter defect. All were non-comparative series. They found a further nine studies 
which had reported 119 patients, with a heterogenous mixture of internal and external sphincter 
defects. Following PNE, 89% progressed onto chronic stimulation. Significant improvements in the 
frequency of incontinent episodes per week from 12.1 to 2.3, and in the Wexner incontinence score 
54
, 
of 16.5 to 3.8 were seen when the data were analysed together. Improvements in the ability to defer 
defecation and in the many quality of life measures were also seen.  
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Systemic sclerosis 
 
SNS was studied in a group of five female patients with systemic sclerosis and faecal incontinence 
66
. 
Four had a successful response to PNE and underwent chronic stimulation. At a median follow up of 
24 months the median frequency of incontinent episodes per week had fallen from 15 (7-25) to zero, 
all patients became continent with an improvement in the ability to defer defecation. 
 
Inflammatory bowel disease 
 
In 2008 Vitton 
67
 reported five patients with faecal incontinence secondary to sphincter disruption 
related to Crohn’s disease, although none had active Crohn’s disease at the time of SNS. All 
underwent PNE followed by chronic stimulation. At a median follow up of 14 (3-36) months all had a 
significant improvements in the Wexner score (median 15 to 6 [p<0.05]), frequency of defecation per 
24 hours (7 to 2 [p<0.05] and in frequency of incontinent episodes per 24 hours (p<0.05).  
 
In 2012 Lehur and colleagues 
68
, reported the effect of bilateral SNS on porcine rectal mucosa. They 
described a reduction in rectal paracellular permeability, reduction in mucosal thickness and an 
increase in mucus on surface epithelium when compared with a control group. They speculated that 
SNS acted to reinforce the rectal mucosal barrier and may be effective for gastrointestinal pathologies 
in which this function is reduced. 
    
 
After rectal surgery (prolapse repair and rectal resection) 
 
Two reports have described SNS following rectal prolapse repair. The first, by Jarrett  in 2005, 
69
 
reported the outcome of four women who had undergone a perineal repair of rectal prolapse. The 
frequency of incontinent episodes per week fell from 11, 24.7, 5 and 8 to zero, 1.5. 5.5 and 1 in the 
four patients with improvement in the quality of life. Robert-Yap 
70
 and colleagues assessed the 
response to SNS of 11 women following prolapse repair. Nine achieved a good response during PNE 
and underwent chronic stimulation. At a median follow up of 36 (12-75) months, there was a 
statistically significant improvement in the frequency of incontinent episodes per week from 15 (13-
20) to five (3-7) (p<0.01). 
 
Six studies have reported the effect of SNS in patients following rectal resection. The first was by 
Matzel and colleagues in 2002 
71
 of a 48 year old male who underwent bilateral stimulation of the 
fourth sacral nerve roots using a dual channelled IPG. At latest follow up, complete continence was 
achieved and there was a reduction in the Wexner incontinence score from 17 to two.  The remaining 
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studies have all reported on the use of unilateral S3 stimulation. All have shown SNS to be an 
effective treatment for these patients 
72-76
. 
 
Congenital sphincter defect 
 
Thomas and colleagues 
77
 reported the outcome of two patients, both born with an imperforate anus, 
who had undergone SNS. One failed to improve with PNE. The other had a successful response to 
PNE and underwent chronic stimulation. He improved from daily incontinence to complete 
continence and an improvement in the ability to defer defecation from two to 15 minutes.  This was 
maintained in the short term. 
 
Spinal pathology 
 
A few studies have examined the effect of SNS in those with spinal pathology. The first was a report 
by Jarrett in 2005
78
. Thirteen patients, with a heterogenous mixture of partial spinal injuries 
underwent PNE. Twelve had a successful response and underwent chronic stimulation. At a median 
follow up of 12 (6-24) months, there was a significant improvement in the frequency of incontinent 
episodes, from 9.33 (7.64) to 2.39 (3.69) (p=0.012) and in the ability to defer defecation from 0-1 
minutes to 5-15 minutes (p=0.022). Gstaltner 
79
 reported its use for those with complete cauda equina 
syndrome. Eight out of 11 achieved a good response to PNE, five underwent chronic stimulation. All 
achieved a significant improvement in their symptoms. Lansen-Koch and colleagues  
80
 reported an 
improvement in incontinent symptoms in three patients with spinal bifida and mixed urinary and 
bowel incontinence. 
 
Cost effectiveness 
 
SNS is expensive. Its current cost in the NHS is around £10500. A replacement battery costs around 
£7000. This will need to be replaced at approximately six years. Follow up of these patients requires a 
specialist medical practitioner to reprogram the device when required. Several cost benefit analyses 
have been performed 
81-85
. All have shown SNS to be cost effective, when compared to the alternative 
treatment. This would be colostomy or continued use of pads and anti diarrhoeal agents. Nonetheless, 
the initial cost of SNS and the benign nature of faecal incontinence, means that it should be offered 
only to those with severe disease who have failed to improve with conservative treatment.  
 
Bilateral SNS 
Bilateral SNS was first reported by Matzel and colleagues in 2002 
71
. Sievert reported its use for 
bladder dysfunction in early complete spinal cord injury
86
. Assuming that SNS works by the 
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activation of multiple ascending sensory neural pathways, then simultaneous stimulation of both third 
sacral nerve roots should activate more of these pathways. It is not unreasonable to speculate that this 
may lead to an improved therapeutic effect. However, this would require two leads and possibly two 
pulse generators. This significant increase in cost would need to be taken into account. 
 
Transcutaneous SNS 
 
Chew and colleagues 
87
 first reported the use of transcutaneous SNS for faecal incontinence in 2011. 
They stimulated the area over S3 unilaterally using five millimetre squared electrode pads. This was 
performed for two hours a day over a three month period. They reported modest, but statistically 
significant, improvements in the Wexner faecal incontinence score. A similar technique was 
employed by Leung in 2013 
88
. They described unilateral S3 stimulation for up to eight hours a day 
over a median period of 10 months. The mean Wexner score improved from 7.9 (4.2) to 4 (3.1) and 
the St Mark’s score 89 improved from 12.7 (5.7) to 5.8 (5.6).  
 
 
Proposed mechanisms of action 
 
The mechanism of action is currently uncertain. A review of the available literature by Gourcerol and 
colleagues in 2011
90
 proposed three possible mechanisms. The first was a neuromodulatory effect on 
somato-visceral reflexes, the second a modulation of the perception of afferent information and lastly 
an effect on external anal sphincter activity.  
 
Many studies have attempted to report changes in anorectal sensory and motor function as a result of 
SNS. There does not appear to be a consistent pattern to these changes in the literature
91
. SNS is also 
effective in those with both acquired and congenital sphincter defects. These issues appear to 
contradict the theory that SNS solely acts upon the sphincter complex. The effect on rectal sensation 
is also uncertain. However, Knowles in 2012 
92
, reported a normalisation of rectal sensory function in 
13 patients with evacuatory dysfunction and rectal hyposensitivity. Despite this, it is unlikely that the 
rectum is the sole target organ for SNS, since it is effective in those who have undergone a rectal 
resection. The effect of SNS upon colonic motility was examined by Michelsen in 2008 
93
. They 
assessed segmental colonic transit times in 20 patients over three weeks. A reduction in overall 
colonic transit time was seen. Patton 
94
 reported a similar outcome in 2013. Using a double blind 
cross-over study design, 11 patients were exposed to suprasensory stimulation and to a period of no 
stimulation, to act as a control. There was significant increase in retrograde colonic propagating 
sequences during stimulation when compared to control (p=0.014).  This is in contradiction to the 
findings of Kamm 
95
, who reported an increase in colonic time in those successfully treated for slow 
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transit constipation, and those of Dinning 
96
 in which there was a significant increase in antegrade 
colonic propagating sequences during stimulation when compared to baseline (p=0.01).  In 2012, 
further work by Dinning and colleagues 
97
 compared suprasensory stimulation to subsensory 
stimulation and to no stimulation in those with slow transit constipation. They reported a significant 
increase in pancolonic antegrade propagating sequences during suprasensory stimulation. Currently, 
SNS is delivered using subsensory stimulation. The results of suprasensory stimulation described 
above have potentially significant implications for the clinical use of SNS.  
 
Several authors have examined the effect of SNS on cortical activity. Giani and colleagues 
98
 
demonstrated an increase in the latency of cerebral somatosensory evoked potentials in patients with 
faecal incontinence and constipation undergoing SNS. Griffin and co-workers 
99
 examined the effects 
of posterior tibial nerve stimulation and SNS on the somatosensory cortex in an animal model. An 
increase in amplitude of primary cortical evoked potentials was seen during stimulation. These 
findings suggest that SNS may alter the representation of the lower gastrointestinal tract in the sensory 
cortex. Lundby and colleagues 
100
 used positron emission tomography to examine brain activity 
during two weeks of SNS. They reported an increase in areas of the frontal cortex associated with 
attention, followed by activation of parts of the caudate nucleus associated with learning and reward 
processing.  
 
The stimulation parameters used for SNS are typically set at a constant pulse width of 210 µsecs and a 
frequency of 14Hz. The lead electrode position and amplitude are variable. The pulse width and 
frequency settings were described by Matzel in 1995 
45
, and are based on the those used for urinary 
disorders 
101
 in early work by Tanagho in the 1980s. A recent double blinded randomised study by 
Duelund-Jakobsen and colleagues in 2012 
102
 examined the effect of altered frequency and pulse 
width in 15 patients with FI. They found that an increased frequency conferred a greater therapeutic 
effect. This echoes earlier work by Dudding 
103
 in which rectal compliance was used a surrogate 
marker of success for 12 patients. They found that an increased frequency and reduced pulse width 
brought an increase in rectal compliance. 
 
Complications 
 
The most common complications of SNS are infection, adverse stimulation and loss or lack of 
efficacy. Infection rates in the larger series vary from 1.6% in 142 patients 
53
 to 10.8% in 120 patients 
104
. In 2011 a meta-analysis of the available literature, found an overall infection rate of 2% in the 995 
patients who underwent PNE and 3% in the 665 who underwent permanent stimulation
105
. Maeda and 
colleagues 
106
 reviewed the prospectively collected data of 176 patients who had undergone SNS. At a 
median follow up of 11 (4-26) months there were 212 episodes of loss of efficacy in 87 patients. 186 
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events of loss of efficacy in 68 patients were found and pain or discomfort occurred 126 times in 67 
patients. Many of these problems were successfully treated by device reprogramming. At 33 (20-52) 
months 31 patients (17.6%) had had their device explanted or treatment discontinued. The large 
prospective series by Hull in 2013
57
, reported that of 76 patients at 5 years, 27 (35.5%) had required 
device revision, removal or replacement.  
 
Discussion 
 
SNS appears to be an effective treatment for faecal incontinence in both the short and longer term. 
This is supported by reported significant improvements in both measures of disease symptoms such as 
frequency of incontinent episodes and incontinence score, and perhaps more importantly, in quality of 
life measures. SNS is reserved for those who have failed to improve with conservative treatment. This 
view is upheld by the guidance from the National Institute for Clinical Excellence in relation to SNS. 
The two main reasons for this are the cost of SNS provision and the potential complications that a 
patient may face.  
 
The absence of studies which directly compare SNS to other treatments is disappointing. This may be 
explained partly by the lack of other comparative effective treatments which are available. For those 
with a sphincter defect, the obvious alternative treatment is sphincteroplasty. A review of the long 
term outcome of sphincteroplasty was performed by Glasgow and colleagues 
15
. They reported initial 
success rates of between 40-85%, which declined over the following five years. However despite the 
worsening symptoms, patient satisfaction and quality of life measures remained high. It remains to be 
seen how sphincteroplasty compares to SNS. 
 
Despite the reported success of those undergoing chronic stimulation, there are a significant number 
of patients who do not benefit from SNS. When SNS, including those undergoing PNE, is analysed on 
an intention to treat basis, around 60% will benefit. This was emphasised by a prospective report of 50 
patients who had undergone PNE, over a follow up of 17 (2-55) months
107
. The authors reported that 
13 (26%) failed to achieve a greater than 50% improvement in symptoms during PNE. Of those who 
underwent chronic stimulation, 10 (20%) failed to achieve at least a 50% improvement. Of the initial 
50 patients, 27 (54%) achieved at least a 50% improvement, of these, 13 (26%) achieved complete 
continence. That left 23 (46%) patients who had failed to benefit from SNS. Of those who had 
obtained benefit from SNS, there may be a loss of efficacy in the longer term. Further treatment for 
these patients is difficult. Improved patient selection is needed to determine which patients are likely 
to benefit most from SNS at an earlier stage. A better understanding of how SNS works may aid this.  
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The outcome measures that are commonly used for SNS must be questioned. To classify a reduction 
of 50% or more of frequency of incontinent as a successful response is misleading. To those with mild 
to moderate disease this may represent a complete cure. However this will not be the case for those 
with severe disease. The effect upon the ability to defer defecation must also be taken into 
consideration. Patients with severe urgency may not experience a significant number of incontinent 
episodes, since they would have made considerable changes to their daily lifestyle in order to 
accommodate this symptom. Symptom scores, such as the St Mark’s score 89, go some way to 
addressing these issues by including the effect of urgency and impact upon daily life. Given that 
faecal incontinence is a benign disease and that a complete resolution of symptoms is difficult to 
achieve, it may be that quality of life measures should be used rather than symptom assessment. 
 
Transcutaneous SNS is interesting. It is cheaper and safer than percutaneous SNS. The two published 
reports 
87, 88
 suggest that it has promise as a treatment for faecal incontinence. Its mechanism of action 
is uncertain. It is difficult to believe that the applied electrical stimulation has any effect upon the 
third sacral nerve root, given the depth of skin, fat and bone that it must traverse first. This implies a 
different mechanism of action to percutaneous SNS. However, the data for this technique are small 
and far from conclusive, and any placebo effect cannot be discounted at this stage. Larger studies are 
needed to investigate this further, and a direct comparison to alternative therapies should be made. 
 
 
3.2 Posterior tibial nerve stimulation for faecal incontinence 
 
Introduction 
 
Posterior tibial nerve stimulation (PTNS) was first used for urinary incontinence by Nakamura et al in 
1983 
108
 and McGuire et al in 1983 
109
. It was first described for faecal incontinence by Shafik in 
2003, who used percutaneous stimulation 
110
. This was followed by the less invasive transcutaneous 
stimulation introduced by Queralto et al 
111
. Since then 12 further studies have investigated its 
effectiveness for faecal incontinence. We have reviewed the results of PTNS by a formal search of the 
literature. Transcutaneous PTNS is performed using an adhesive electrode pad placed over the 
posterior tibial nerve, in a position posterior and superior to the medial malleolus. Percutaneous PTNS 
utilises an electrode needle instead. For both techniques a ground pad is placed nearby. 
 
 
 
 
Method 
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A review was performed of all the evidence published on posterior tibial nerve stimulation for faecal 
incontinence. An electronic search was performed of the Medline, Pubmed and Embase databases 
using the keywords and/ or MeSH “tibial”, “faecal incontinence”, “neuromodulation”, “stimulation”. 
Further relevant studies were identified by cross referencing from relevant articles and abstracts. Only 
studies that reported the clinical outcome of PTNS for faecal incontinence in the English language 
were included (see table 1). 
 
Results 
 
Table 1 summarises the study type, study population, modality of PTNS used, regimen of PTNS used 
and the level of evidence for each study. Table 2 summarises the different outcome measures used for 
each study. 
 
Percutaneous PTNS 
 
Shafik, in 2003 
110
 described thirty two patients, all with idiopathic faecal incontinence, who had 
received percutaneous PTNS.  All had an intact sphincter, and had failed biofeedback and other 
conservative treatment. They received 30 minutes of stimulation on alternate days for a period of four 
weeks. This group was compared with 20 untreated control patients. The primary endpoint was >50% 
improvement in a faecal incontinence score, similar to the Wexner FI Score 
112
. A > 50% 
improvement in the continence score occurred in 27 (84%) of patients treated, nine (29%) of whom 
experienced a relapse during a mean period of 22.3 ± 4.6 [SD] months.  Six of these patients 
benefitted from further “top-up” therapy. It is unclear whether randomisation or matching of the two 
groups were attempted, or how the control group was managed or how they compared with the 
treatment group. The follow up period ranged from 16 to 30 months.  
 
De la Portilla 
113
 described 16 subjects treated by PTNS for 30 minutes once a week for three months. 
All had failed conservative therapy, and all had an intact sphincter. A statistically significant 
reduction in the Wexner faecal incontinence score was seen immediately after treatment, which was 
maintained at a 3 month assessment. The reduction in the number of incontinent episodes was, 
however, not statistically significant. Maximal anal canal squeeze pressure was significantly 
increased. 
 
In a prospective multicentre study 22 patients received twice weekly 30 minute PTNS for six weeks 
114
. All had failed conservative treatment and none had a significant sphincter defect. Treatment was 
continued weekly, then biweekly and finally monthly. At six weeks 14 (63%) had a greater than 50% 
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reduction in incontinent episodes, but this was not statistically significant. If symptoms reappeared or 
worsened, then treatment reverted to the last effective treatment schedule and was continued for one 
year. At one year assessment, there was a significant reduction in incontinence episodes in the 14 
patients, who remained in the study. There was a statistically significant reduction in the Wexner 
faecal incontinence score at six weeks, three months and one year after PTNS.  A significant 
improvement in the SF-36 health related quality of life score at one year was also seen.  Anorectal 
physiological parameters were not assessed. 
 
In a retrospective report of 13 patients, 
115
 PTNS was given weekly for 30 minutes for three months. 
Using prospectively collected data, a statistically significant reduction in incontinent episodes was 
demonstrated. This improvement was maintained at one month follow up.  
 
Three prospective studies of percutaneous PTNS were reported from the same institution 
116-118
. The 
largest of these 
118
 included 100 patients having twelve 30 minute sessions either twice weekly over 
six weeks or once weekly over 12 weeks. The patients were divided into groups according to the type 
of incontinence, whether passive or urge. In patients with passive incontinence there was no 
significant difference in the Wexner score (11.5±4.1 before; 9.41 ±4.3 after), urgency (5 minutes 
before; 12 minutes after) and the number of incontinent episodes (median 4/week before; 3/week 
after). There was a significant improvement in the depression and lifestyle domains of the Rockwell 
faecal incontinence quality of life score (2.85+/-0.79 to 3.23+/-0.87, and 2.96+/-1.1 to 3.14+/-1.06 
respectively). In the urge incontinence group there was a statistically significant improvement in the 
Wexner FI score (11± 4.1 before; 8.3 ± 4.8 after), urgency (1 minute before; 5 minutes after) and in 
the number of incontinent episodes per week (median 4 before; 0 after). There were significant 
improvements in the coping and depression domains of the quality of life score (1.43+/-0.36 to 
1.92+/-0.73, and 2.36+/-0.63 to 2.88+/-0.79 respectively). In patients with both passive and urge 
incontinence, there was a significant difference in the Wexner FI score (12.8 ± 3.7 before; 9.1 ±4.4 
after), urgency (1 minute before; 5 minutes after) and the number of incontinent episodes per week 
(median 5 before; 1 after).  All domains of the quality of life score improved significantly (Lifestyle: 
2.4+/- to 2.9+/-0.93, Coping: 1.74+/-0.61 to2.36+/-0.77, Depression: 2.89+/-0.91 to 3.27+/-0.77, 
Embarrassment: 2.03+/-0.89 to 2.6+/-0.89). 
 
Transcutaneous PTNS 
 
In a prospective uncontrolled study 
111
, ten patients received daily treatment for 20 minutes for four 
weeks. All had an intact sphincter and had failed biofeedback. A statistically significant improvement 
of more than 60% in the Wexner FI score was reported, which was maintained at a 12 week 
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assessment. It is unclear whether this was statistically significant. There was no statistically 
significant change in anal canal pressures.  
 
Twenty four patients 
119
 received 20 minute daily sessions for three months. All had failed 
conservative therapy, but no data on the integrity of the anal sphincter were given.  There was no 
statistically significant difference in the Wexner FI score before and after treatment. Those with 
evidence of improvement were offered further treatment. On assessment at a mean of 15 months, this 
improvement was maintained. Anorectal manometry was not performed. 
 
Another study included 32 patients treated twice daily for one month 
120
. The primary endpoint was a 
visual analogue score simply to assess overall benefit. Secondary endpoints included the Wexner FI 
score and a faecal incontinence quality of life score 
121
. Twenty (62.5%) recorded a greater than 10% 
improvement in the visual analogue score. There was also a statistically significant improvement in 
the mean Wexner faecal incontinence score (14.5 to 11), which was maintained at three and six 
months, following further top-up treatment. 
 
Percutaneous compared with Transcutaneous PTNS 
 
Percutaneous and transcutaneous PTNS has been compared in only one study
122
. Patients were 
randomised to three groups, percutaneous (n=11), transcutaneous (n=11) and a sham transcutaneous 
stimulation group (n=8) acting as a placebo. All groups had twice weekly 30 minute treatment 
sessions for six weeks. Nine of the percutaneous group reported a greater than 50% reduction in 
incontinent episodes, compared with five in the transcutaneous group.  A statistically significant 
improvement in soiling episodes was seen in the percutaneous group and not in the transcutaneous 
group. A statistically significant reduction in the St. Mark’s FI score 89 was seen in the percutaneous 
(19 before; 12.7 after) and transcutaneous (18.5 before; 14.7 after) groups. No improvement was seen 
in the sham group. The percutaneous group showed a statistically significant improvement in the 
ability to defer defecation (1.9 minutes to 6.7 minutes). No improvement in deferral time was seen in 
the transcutaneous or sham groups. There were no significant changes in anal canal pressures.  
 
 
Transcutaneous PTNS compared to sham stimulation 
 
Leroi and colleagues compared unilateral transcutaneous PTNS with sham stimulation in 2012 
123
. In 
this study, 144 were randomised to receive three months of treatment or sham, the study was double-
blinded. The treatment group received 20 minutes of therapy twice daily for three months, with the 
amplitude set at sensory level. The sham group received the same frequency of treatment using a 
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dummy box which did not deliver a current. The frequency of incontinent episodes per week fell 
significantly in the treatment group from 1.7 (0-23) to 1 (0-14.3) (p=0.004). There was a non-
significant reduction in the sham group from 2.9 (0-25) to 1.6 (0-23.6) (p=0.06). The Wexner FI score 
fell significantly in both groups. However, 47% of the treatment group achieved a ≥30% reduction in 
the Wexner score compared to only 27% of the sham group (p=0.02). However, on intergroup 
analysis, there was no significant difference found between the two groups. This suggested that 
unilateral transcutaneous PTNS may be no more effective than placebo. 
 
PTNS and Spinal Injury 
 
A case series by Mentes in 2007 
124
 described the use of percutaneous PTNS in two incontinent 
patients with partial spinal cord injury. PTNS was given several years following the injury. Both 
received 30 minutes of PTNS on alternate days for four weeks. There was an improvement in the 
Wexner score, Rockwood faecal incontinence quality of life score, anal resting and squeeze pressures 
and rectal sensory thresholds.  
 
PTNS and Inflammatory Bowel Disease 
 
Twelve patients with inflammatory bowel disease of mixed aetiology underwent self-administered 
transcutaneous PTNS 
125
 for three months. The primary endpoints included change in the Wexner 
score and in a visual analogue scale (0-5) to assess subjectively improvements in bowel function and 
quality of life. PTNS failed to improve the Wexner score and in patients with Crohn’s there was no 
improvement in the Harvey-Bradshaw index 
126
. Subjective improvement in symptoms was recorded 
in 42% and in quality of life in 50%. No statistical tests were applied. 
 
 
Discussion 
 
It is uncertain how PTNS works. It is thought to neuromodulate the sacral nerve plexus remotely via 
the posterior tibial nerve; so ultimately having a similar action to SNS. The exact mechanism of action 
of SNS is uncertain. It is likely to be the result of multiple different physiological effects 
90, 127
, such as 
alteration of local somato-visceral reflexes leading to changes in colonic motility and anal sphincter 
activity, and also modulation of higher perception of afferent information 
98, 99
. There are no anorectal 
physiological changes consistently observed from PTNS, this is also the case with SNS 
91
. The 
acupuncture point ‘‘sanyinjiao’’ or ‘‘spleen-6”, overlies the posterior tibial nerve near the ankle. 
Chang and colleagues 
128
 reported the effects of acupuncture stimulation of this point in patients with 
lower urinary tract dysfunction.  An improvement was seen in the majority of the patients.  A small 
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study by Scaglia and colleagues 
129
, reported improvement in faecal continence using acupuncture. 
One of the acupuncture points used here corresponded to the position of the posterior tibial nerve. No 
work published to date has directly compared acupuncture with PTNS. 
 
PTNS is usually delivered unilaterally, at the nerve’s most superficial position above and behind the 
medial malleolus. It does not matter which leg is used. There has been no suggestion of any 
dominance of the left or right tibial nerve, although work has been done in relation to dominance of 
the pudendal nerve and its effect on anal sphincter activity 
130
.  A frequency of 10-20 Hz and a pulse 
width of 200 µsecs are usually used for PTNS, these are similar to the settings used for SNS.  It has 
been 
103
 suggested that a shorter pulse width and a higher frequency may improve faecal incontinence 
in patients receiving SNS. There is no published work investigating the effect of altering these 
parameters in PTNS. The optimum duration and frequency of treatment have yet to be determined. 
The published literature describes a diverse range of treatment schedules (table 1). The therapeutic 
effects of SNS are short-lived once treatment has stopped. Much of the literature suggests that there is 
a residual therapeutic effect after PTNS treatment finished. It is unclear how long this can last for, and 
how this is related to the initial treatment regimen and modality of PTNS used. Govaert 
114
 described a 
reduced frequency of “top-up” treatments to maintain efficacy once the initial treatment had been 
completed. The frequency of treatment could then be increased if the patient’s symptoms relapsed. 
Hotouras employed a similar top-up therapy regimen, although did not report the outcome of this. 
 
PTNS is an attractive treatment option because of the ease with which it can be administered, and its 
apparent low cost. A reusable PTNS stimulator device costs £800 and a box of single use 
percutaneous needle electrodes costs £380 
117
. The transcutaneous electrode pads can be reused for 
each patient, and cost approximately one pound each. In comparison, SNS costs in excess of £9000 
for equipment alone 
84
 and requires an operating theatre. It may be that the effect of repeat PTNS 
administration will cause this difference to narrow in the longer term. No analyses were found 
assessing the cost effectiveness of PTNS for FI. SNS carries with it the risk of potentially significant 
complications 
106, 131
, none of which have been reported from PTNS.   
 
Govaert and colleagues 
114
 reported 60% of their patients had achieved a 50% or more reduction in 
incontinent episodes. George and colleagues 
122
 reported 82% of the percutaneous arm of their study 
achieved a 50% or more reduction in incontinent episodes. These short term outcomes compare 
favourably with those seen from SNS. It is uncertain how SNS and PTNS compare in the longer term. 
The longest reported follow up for PTNS is 30 months 
110
. Unfortunately a composite FI score was 
used in this study, rather than change in frequency of incontinent episodes. Govaert’s work described 
a follow up of 12 months, during which a statistically significant reduction in incontinent episodes 
had been maintained. Disappointingly, six studies did not use the change in incontinent episodes as an 
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outcome measure at all. Instead, a FI score was used as a primary endpoint. Two studies even used a 
visual analogue score to measure outcome.  The effect of PTNS on defecatory urgency is under 
reported. Only four studies described the effect of PTNS on the ability to defer defecation. Because of 
these differences in outcome reporting (see table 2), comparisons between the studies are difficult to 
make.  
 
George and colleagues 
122
attempted to compare transcutaneous PTNS with percutaneous PTNS. When 
the treatment modalities were compared individually, a significant improvement in soiling was only 
seen from percutaneous PTNS. However, statistically, it is not clear if this equated to superiority of 
percutaneous PTNS over transcutaneous PTNS. This study was likely to have been limited by the 
number of patients used, with only 11 in each treatment group.  It is worth noting also, that 
transcutaneous PTNS was administered twice weekly in this study. This is in contrast to the treatment 
regimens described by Queralto 
111
, Vitton 
119, 125
 and Eleouet 
120
, in which transcutaneous PTNS was 
administered on at least a daily basis.  
 
SNS can be an effective treatment for patients with FI secondary to partial spinal cord injury 
78
. The 
case series by Mentes reported PTNS in patients with FI and partial spinal cord injuries, this 
suggested some promise. However, this is a very small series, and it is difficult to draw any firm 
conclusions. The use of PTNS in this patient group deserves to be investigated further. The results of 
PTNS in patients with inflammatory bowel disease are disappointing. This contrasts to previous work 
from the same group, in which SNS was reported to have improved FI in patients with Crohn’s and 
co-existing sphincter defects 
67
.  
 
Hotouras is the only author to report the differing outcome for each FI sub-group. This work 
suggested that those with passive incontinence did not benefit as much as those with urge or 
combined FI. However, the passive FI group was small (n=15) compared to the urge FI and combined 
FI groups (n=25 and n=60 respectively). It is uncertain if this poor outcome would still be evident if 
larger patient numbers are used. 
 
The 14 studies published so far contain many defects of design including retrospective collection of 
data, small numbers and absence of a comparative group. There is also a wide variation in the 
outcome measures used. Two randomised controlled trials and one non-randomised controlled trial 
were identified. The remaining studies were non-comparative case series. The quality of evidence has 
been graded in table 1 
132
. Overall, the quality of evidence is poor and there is marked heterogeneity 
of treatment technique and outcome measures employed. Because of this, at present it would not be 
possible to perform any summative analysis, such as meta-analysis, of the evidence base.  
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There is evidence that PTNS is an effective treatment for faecal incontinence in some patients and that 
a response is maintained over several months, and can be improved by top up treatment if efficacy 
declines with time. Further work is needed to compare PTNS to more established treatment modalities 
using large randomised controlled trials, and to investigate how its efficacy can be improved. More 
consistent and robust reporting of outcome is needed. The efficacy of PTNS in the longer term needs 
to be investigated too. 
 
3.3 Pudendal nerve stimulation for faecal incontinence 
 
Introduction 
 
In recent years, neuromodulation, in the form of sacral nerve stimulation (SNS), has become the first-
line surgical treatment when non-operative methods fail 
45
. The short and long-term effects of SNS 
have been widely reported 
133, 134
. When SNS is evaluated on an intention to treat basis, around 60% of 
patients will experience a ≥50% reduction of incontinent episodes, and around 30% will become fully 
continent 
55
.  Approximately one-third of patients will not improve significantly with chronic 
stimulation in the short term. There will also be those patients who lose efficacy over the longer term. 
Further treatment of these patients is difficult, many may progress to a defunctioning colostomy.  
 
SNS is believed to work, in part, by the activation of ascending afferent fibres in the sacral nerve roots 
135
. Stimulation leads to modulation of local reflex pathways at the spinal cord level, which are 
integral to colonic, rectal and pelvic floor function 
90
. Central effects on the sensory cortex and 
cerebral evoked potentials have also been described 
98, 99
. One limitation of sacral nerve stimulation is 
that usually only one nerve root is stimulated. The afferent outflow from the pelvic floor, distal bowel 
and anal sphincter is predominantly found in the S2 and S3 roots and in some patients may be 
asymmetric or at a single level 
130, 136
. Sacral nerve stimulation is most frequently performed at the 
level of the S3 root as direct S2 root stimulation can lead to adverse effects with pain experienced in 
the buttock, leg or foot. Absence of afferent outflow at the S3 level may explain why sacral nerve 
stimulation fails to benefit some patients. The pudendal nerve is derived from three sacral nerve roots, 
S2-S4. In theory, greater afferent stimulation can be achieved by stimulation of this nerve than by 
stimulation of a single sacral nerve root. In some patients this may translate to an improved 
therapeutic effect. In addition as the pudendal nerve is an isolated structure at the level of the ischial 
spine there is less risk of unwanted stimulation of adjacent nerve roots. PNS has been used in a small 
number of patients with urinary voiding dysfunction and interstitial cystitis, including patients that 
have failed to benefit from SNS 
137, 138
.  
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Methods 
 
A review was performed of all the evidence published on pudendal nerve stimulation (PNS) for faecal 
incontinence.  An electronic search was performed of the Medline, Pubmed and Embase databases 
using the keywords and/ or MeSH “pudendal”, “faecal incontinence”, “neuromodulation”, 
“stimulation”. Further relevant studies were identified by cross referencing from relevant articles and 
abstracts. Only studies that reported the clinical outcome of pudendal nerve stimulation for faecal 
incontinence in the English language were included. 
 
Technique for PNS  
 
PNS requires a period of test stimulation. This can vary from one to three weeks in duration. This is to 
predict the likely outcome to chronic PNS. A successful response can be defined as a ≥50% 
improvement in symptoms of faecal incontinence, in a similar fashion to that used for SNS. This 
response can be measured in frequency of incontinent episodes, or incontinent days. Pudendal nerve 
stimulation is delivered using a Medtronic model 3093 lead (Medtronic Inc, Minnesota, USA) 
inserted percutaneously under general anaesthesia. This can be performed using a transgluteal 
approach 
139
, in which the lead insertion point is at the intersection of a horizontal line from the 
greater trochanter of the hip and a vertical line from the ischial tuberosity. Correct lead placement is 
confirmed by contraction of the external anal sphincter. This can be assessed by electromyographic 
analysis, or by placing a finger in the anus. The alternative technique is an infra-gluteal approach 
138
. 
Here, the lead insertion point is at the midpoint of a line between the ischial spine and the anus. 
Correct lead placement is best confirmed by electromyographic analysis. The PNS lead is connected 
to an external stimulator via a percutaneous extension (Test stimulator 3692, Medtronic Inc, 
Minnesota, USA). Test stimulation is performed at a sub-sensory level for a three-week period. 
During this period all the patients keep a bowel habit diary to record the response of the therapy on 
their symptoms. If an unsuccessful response is experienced, then the lead is removed at three weeks. 
If a successful response has been experienced, then the lead is connected to an implantable pulse 
generator (IPG) placed in the ipsilateral buttock (model 3023 or model 3058, Medtronic Inc, 
Minnesota, USA). Stimulation is set to the parameters traditionally used for sacral nerve stimulation 
at a pulse width of 210µsec and pulse frequency of 14Hz. Electrode configuration was altered so that 
the sensory stimulus was felt in the perianal area. 
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Results  
 
Pudendal nerve stimulation for FI was first described by Matzel and colleagues 
140
 in 2005. They 
reported the use of a Bion microstimulator (Advanced Bionics Corporation, CA, USA) to stimulate 
the pudendal nerve, for a patient with bowel and bladder dysfunction following an extensive pelvic 
fracture. They reported an improvement in frequency of incontinent episodes of eight to two per 
week, at a follow up of 10 months.  Bock et al 
141
 reported the first use of the Interstim device 
(Medtronic Inc, Minnesota, USA) for PNS. This was applied to two patients who had failed to 
improve with SNS. At four months follow up the patients’ symptoms improved from four and seven 
incontinent episodes per day respectively to complete continence.  
 
 
Discussion 
 
At present, there is a paucity of published data to support the use of PNS for faecal incontinence. PNS 
requires two operations three weeks apart, after the test period has finished. This is because the PNS 
lead has to be removed or connected to the IPG at this point. Whichever of these actions is taken, both 
require an operation. This differs to SNS, in which the test lead can be removed in the outpatient 
clinic, and chronic stimulation can be arranged at convenient time. It is the author’s opinion that PNS 
is a more difficult procedure to perform than SNS. For these reasons it is unlikely that PNS will 
supersede SNS, unless PNS is shown to have significantly superior efficacy. No published studies 
have attempted to directly compare them for FI. Peters and colleagues 
142
 compared the two for 
patients with bladder voiding dysfunction. They described 30 patients, who had undergone a single 
blinded randomised cross-over trial. Symptom relief obtained by PNS was greater than that obtained 
by SNS in 80% of patients.  
 
PNS may find a role as a second line treatment after SNS.  This makes sense, when one considers that 
increased number of afferent sensory pathways which are stimulated during PNS. Larger studies are 
needed to examine this further. It is a more attractive treatment option in those who have failed 
chronic SNS. In such patients, there is no need for a second operation immediately after the test 
period, since the PNS lead can be connected to the SNS IPG during the first operation. 
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Table 1- Table to show the method of PTNS and treatment regime. 
Author, Year Subject 
Number 
Modality of 
PTNS 
Duration of 
Therapy 
Frequency of 
Therapy 
Study Type Level of 
Evidence 
Shafik, 2003 32 Percutaneous 4 weeks Alternate days Non-randomised 
controlled trial 
IIIB 
Queralto, 2006 10 Transcutaneous 4 weeks Daily Prospective 
Uncontrolled 
IV 
Mentes, 2007 2 Percutaneous 4 weeks Alternate days Prospective 
Uncontrolled 
IV 
Vitton, 2009 12 Transcutaneous 12 weeks Daily Prospective 
Uncontrolled 
IV 
De La Portilla, 
2010 
16 Percutaneous 12 weeks Weekly Prospective 
Uncontrolled 
IV 
Vitton, 2010 24 Transcutaneous 12 weeks Daily Prospective 
Uncontrolled 
IV 
Govaert, 2010 22 Percutaneous 6 weeks Twice weekly Prospective 
Uncontrolled 
IIB 
Boyle, 2010 ● 31 Percutaneous 12 weeks Weekly Prospective 
Uncontrolled 
IV 
Findlay, 2010 13 Percutaneous 12 weeks Weekly Retrospective 
Uncontrolled 
IV 
George, 2010-A 
* 
11 Transcutaneous  6 weeks Twice weekly Randomised 
Controlled Trial 
IIB 
George, 2010-B 
# 
11 Percutaneous 6 weeks Twice weekly Randomised 
Controlled Trial 
IIB 
Eleouet, 2010 32 Transcutaneous 4 weeks Twice daily Prospective 
Uncontrolled 
IV 
Allison, 2011 ● 90 Percutaneous 6 or 12 weeks Twice weekly or 
Weekly 
Prospective 
Uncontrolled 
IV 
Hotouras, 2011 
● 
100 Percutaneous 6 or 12 weeks Twice weekly or 
Weekly 
Prospective 
Uncontrolled 
IV 
Leroi, 2012 144 Transcutaneous 
compared to 
sham 
3 months Twice daily Randomised 
Controlled Trial 
IIB 
*refers to the transcutaneous PTNS arm of the study 
#refers to the percutaneous PTNS arm of the study 
● same institution with likely duplication of results.  
Levels of evidence according to the Oxford Centre for Evidence Based Medicine. OCEBM Levels of Evidence Working Group*. "The 
Oxford 2011 Levels of Evidence”. Oxford Centre for Evidence-Based Medicine. http://www.cebm.net/index.aspx?o=5653 
* OCEBM Table of Evidence Working Group = Jeremy Howick, Iain Chalmers (James Lind Library), Paul Glasziou, Trish Greenhalgh, 
Carl Heneghan, Alessandro Liberati, Ivan Moschetti, Bob Phillips, Hazel Thornton, Olive Goddard and Mary Hodgkinson 
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Table 2- Table to show the differing treatment outcome measures used (“Yes” indicates inclusion as an outcome measure, 
“No” indicates non-inclusion as an outcome measure) 
Author, Year FI Score 
Change 
 
FI episode 
change/ 
week 
Ability to defer 
defecation/ 
mins 
Patient centred 
subjective 
assessment of 
bowel function 
SF-36 QOL 
Change 
Rockwood FI-
QOL Score 
Change 
Shafik, 2003 Yes- 
Composite FI 
score 
No No No No No 
Queralto, 2006 Yes- Cleveland 
Clinic FI score 
No No No No No 
Mentes, 2007 Yes- Cleveland 
Clinic FI score 
No No No No Yes 
Vitton, 2009 Yes- Cleveland 
Clinic FI score 
No No No No No 
De La Portilla, 
2010 
Yes- Cleveland 
Clinic FI score 
Yes No Yes No Yes 
Vitton, 2010 Yes- Cleveland 
Clinic FI score 
No No Yes No No 
Govaert, 2010 Yes- Cleveland 
Clinic FI score 
Yes No No Yes 
 
Yes 
Boyle, 2010● Yes- Cleveland 
Clinic FI score 
Yes Yes No No No 
Findlay, 2010 No Yes No No No Yes 
George, 2010-
A 
Yes- St Mark’s 
FI score 
Yes Yes No Yes Yes 
George, 2010-
B 
Yes- St Mark’s 
FI score 
Yes Yes No Yes Yes 
Eleouet, 2010 Yes- Cleveland 
Clinic FI score 
No No Yes No No 
Allison, 
2011● 
Yes- Cleveland 
Clinic FI score 
Yes Yes No No No 
Hotouras, 
2011● 
Yes- Cleveland 
Clinic FI score 
Yes Yes No No Yes 
Leroi, 
2012 
Yes- Cleveland 
Clinic FI score 
Yes Yes No No Yes 
 
● refers to the fact that these studies all originated from the same institution and likely duplicate reporting of patient 
outcomes has occurred. 
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Chapter 4 
 
Neuromodulation for constipation 
 
4.1 Sacral Nerve Stimulation for Constipation 
 
Introduction 
Sacral nerve stimulation was first reported for bladder dysfunction in 1982 
44
 and for faecal 
incontinence in 1995 
45
. Its use for constipation was first reported in 2001. 
 
Method 
A review was carried out of all the evidence published on the use of SNS for chronic constipation. An 
electronic search was performed using Medline, Pubmed and Embase, with the keywords and/ or 
MeSH headings of “constipation”, “sacral nerve stimulation”, and “sacral neuromodulation”. Further 
studies were identified by cross referencing from relevant articles and abstracts. Only studies that 
reported the clinical outcome of SNS for constipation in the English language were included in this 
review. The aim of this review was to assess the clinical efficacy of SNS for constipation using the 
current published literature. 
 
Mechanism of action 
The mechanism of action of SNS is unclear. It is likely to involve multiple physiological effects, in 
particular modulation of afferent and local reflex pathways 
90
. The S2 root has the greatest afferent 
outflow from the sacral plexus 
136
, however stimulation of this root often leads to activation of sciatic 
motor fibres that can lead to buttock and leg pain. Therefore stimulation of the S3 root is often the 
preferable option for therapy providing maximal sacral afferent stimulation in the absence of 
unwanted side-effects. The proposed mechanisms of action of SNS have been described in chapter 
two. A few studies have attempted to determine this mechanism of action in relation solely to 
constipation. Knowles and colleagues reported a double-blinded randomized study to assess the effect 
of sacral nerve stimulation on rectal sensation in patients with rectal hyposensitivity. They suggested 
that modulation of afferent pathways may be important as improvement in threshold and maximal 
tolerated volumes to balloon distension occurs with therapy 
92
. The effects of SNS on colonic motility 
were investigated by Dinning and colleagues in 2007 
96
. They showed that SNS at supra-sensory 
threshold significantly increased antegrade pan-colonic wave sequence in patients with slow transit 
constipation. This corresponded to an increase in frequency of defecation and a reduction in laxative 
use. However, stimulation at sub-sensory threshold, as used routinely in clinical practice, may not 
have an effect on motility
97
. However Kamm in 2010 
95
, showed normalization of whole gut transit 
time at six months follow-up in one-half of patients undergoing SNS for slow transit constipation 
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using stimulation at sub-sensory threshold . This corresponded to an increase in frequency of 
defecation. In contrast, sacral nerve stimulation in patients with faecal incontinence may reduce 
anterograde colonic transit 
93
. The difference in the effect of stimulation with different conditions 
remains unclear but sacral nerve stimulation may act to normalise transit by modulation of the enteric 
nervous system or reflex pathways at the spinal cord level. 
 
 
SNS and constipation 
Thirteen published studies were found reporting the use of SNS for constipation (Table 1). Ten 
referred to adults, two of which were double-blinded cross-over studies, and three were retrospective 
reviews. Three studies reported the use of SNS in children and adolescents. 
 
Ganio and colleagues in 2001 
48
 described 40 patients suffering from a variety of functional anorectal 
and urinary disturbances, of whom 12 had constipation. These patients were subjected to ten days of 
PNE. Ten of these patients completed a week’s course of stimulation. This group showed no increase 
in the number of bowel movements per week however there was improvement in initiating evacuation 
and reduction in the number of unsuccessful visits to the toilet and time required to evacuate.  
 
Malouf and colleagues in 2001 
143
 exposed eight patients to three weeks of PNE, all of whom had 
slow-transit constipation. Two patients demonstrated an increase in the frequency of spontaneous 
defecation over the test period and an improvement in bowel function as assessed by visual analogue 
score. The remaining six showed no improvement.  
 
More convincing results were reported by Kenefick in 2002 
144
. Four women with constipation were 
exposed to PNE and then to permanent SNS. Two patients had slow transit constipation and two had 
dyssynergia on defecation proctography. An increase in the number of spontaneous defecations and 
an improvement in abdominal pain and bloating were demonstrated at six month follow-up. 
Improvements in the Cleveland Clinic constipation score 
145
 and in a visual analogue score were seen. 
In a subsequent study, Kenefick and colleagues 
146
 described a double-blinded placebo controlled 
crossover study using two of these patients. Improvement in defecatory frequency, abdominal pain, 
bloating and a visual analogue score was demonstrated when the stimulator was switched on, 
compared to when it was off.  
 
In 2008, Holzer and colleagues 
147
 described 19 patients who underwent temporary SNS. 42% of these 
had slow transit constipation and 47% had evacuatory dysfunction. Only eight patients (42%) were 
deemed eligible for permanent stimulation defined as improvement of evacuation frequency to 
achieve two or more defecations per week or defecation without digitation. Clinical benefit was 
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maintained with chronic stimulation at a median follow-up of 11 months with associated reduction in 
the Cleveland Clinic constipation scores (median (range) 23 (18-27) at baseline to 8 (4-13) at 12 
months) and SF-36 quality of life scores 
148
.  
 
A retrospective study by Naldini and colleagues in 2010 
149
 described the outcome of 15 patients with 
slow transit constipation who had undergone PNE. Of these, nine (60%) met the study criteria for 
placement of a permanent implant. The criteria for permanent SNS was defined as disappearance of 
the need for laxatives or enema use, occurrence of spontaneous defecation or an increase in SF-36 
quality of life score. At 6 months follow-up there was a significant increase in the number of bowel 
movements per week (mean 1.8 at baseline to 3.3 at 6 months) with concurrent reduction in the 
number of enemas required. The Cleveland Clinic constipation improved from 24 at baseline to 12 at 
6 months with improvement in all domains of the SF-36 quality of life score.  
 
The largest prospective study to date was carried out by Kamm and colleagues in 2010 
95
. In this 
multicentre international study 62 patients underwent test stimulation, 50 (81%) of whom had slow 
transit constipation.  Forty five (73%) progressed to permanent stimulation. The criteria for 
progression onto permanent SNS included a frequency of evacuation of three or more times per week, 
a reduction of 50% or more in the number of evacuations associated with straining or a 50% decrease 
in the sensation of incomplete evacuation. The patients were followed for a median of 28 months. 
Thirty nine (87%) of those who had undergone permanent stimulation, showed an improvement in 
symptoms, including frequency of defecation, straining, sensation of incomplete evacuation, 
abdominal pain and bloating. The Cleveland Clinic constipation score improved from 18 at baseline to 
10 at latest follow-up with a visual analogue score that rated overall bowel function increasing from 8 
to 66 (where 0 was equal to worst function and 100 equal to best function). Significant improvements 
were seen in four of the eight domains of the SF-36 health questionnaire. Rectal sensation was altered 
with stimulation with reduction in the sensory, urge and maximal thresholds to rectal balloon 
distension. One half of patients with slow gut transit at baseline normalised colonic transit time at six 
months and this improvement corresponded to an increase in frequency of defaecation. 
 
Sharma and colleagues published a retrospective study in 2011 
150
. Twenty one patients had 
undergone temporary stimulation, 86% of whom had slow transit constipation. Of these 11 (52%) 
went on to have a permanent implant. Frequency of defecation increased from a median of one 
defecation per week at baseline to a median of four per week at 34 months follow-up. Eight of these 
11 patients completely stopped laxative medication. 
 
A recent retrospective study by Govaert and colleagues 
151
 reported 117 patients who had undergone 
PNE. Of these 68 (58%) proceeded to permanent SNS. Some of the patients were part of the multi-
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centre study published by Kamm 
95
. There was an initial significant improvement in the Cleveland 
Clinic constipation score from 17 (3.8) to 10.2 (8.3) at first follow-up. This improvement was 
maintained at a median follow up of 37 months. Data regarding pathogenesis of constipation were 
incomplete but both patients with slow transit constipation and evacuatory dysfunction appeared to 
benefit from treatment. 
 
Carriero and colleagues
152
 suggested that psychological assessment may aid the selection of patients. 
In this study, 68 patients with slow transit constipation were offered psychological assessment using 
the MMPI-2 (Minnesota Multiphasic Personality Inventory-2) questionnaire 
153
. Forty-five completed 
the questionnaire.  Thirteen had a normal score, and underwent PNE. Of these, 11(85%) proceeded to 
permanent stimulation. Nine of those who had refused the MMPI-2 questionnaire or had an abnormal 
score also underwent PNE. Of these, only three progressed onto permanent stimulation (33%).  
 
SNS in children with constipation 
Two studies reported the effect of SNS in children with severe dysfunctional elimination syndrome. 
This syndrome includes a broad spectrum of functional disturbances involving the urinary and lower 
gastrointestinal tract in the absence of any obvious anatomical or neurological deficiency. One of the 
problems experienced by these children is constipation. The first study
154
, described 23 children, of 
whom 15 were experiencing constipation type symptoms. The patients’ age ranged from six to 15 
years. After a mean follow up of 13 months, constipation improved in 12 out of the 15 patients treated 
with permanent SNS. The next study by Roth and colleagues in 2008 
155
 described 17 children with 
constipation type symptoms, in 12 children these symptoms either resolved or improved following 
SNS. The age range in this study was 8-17 years but it is unclear in both studies how symptoms 
improved since no objective measurements were described. 
 
Van Wunnik and colleagues described a retrospective study, in which 13 female adolescents 
underwent PNE for constipation 
156
. The age range of these patients was ten to 18 years, and all had 
failed conservative therapy. Twelve underwent placement of a permanent implant. At a follow up of 
between six to 12 months, there was an improvement in the number of defecations per week, 
abdominal pain, straining and in the Cleveland Clinic constipation score. Absence from school was 
noted in ten of these patients at baseline, however at six months follow up, all were attending school 
regularly 
156
. 
 
Adverse events with SNS and constipation 
 
A retrospective review by Maeda and colleagues 
157
 described the suboptimal outcome and 
complications observed in an individual unit from SNS for constipation.  Thirty eight patients had 
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undergone permanent stimulation, 22 (58%) of whom had an adverse event specifically related to 
their treatment. Nearly half of the events resolved with re-programming, however a third needed a 
further surgical procedure. Kamm and colleagues 
95
 reported 61 adverse events in 45 permanent 
implants specifically related to the treatment. Another 40 adverse events were attributed to the 
underlying constipation or to a new unrelated diagnosis. Two thirds of the SNS related adverse events 
were self-limiting, and most required re-programming of the device. Although the frequency of these 
adverse events appears high, it is unclear as to the proportion of subjects affected. These reports 
would appear to be comparable to those observed from the use of SNS for faecal incontinence. Maeda 
et al found that 85% of those with a permanent implant for faecal incontinence reported an adverse 
event, with the majority relating to a loss of efficacy
106
  
 
 
Discussion 
Chronic constipation is common. It should initially be managed by a combination of pharmacological 
agents, rectal irrigation and/or behavioural treatments. There is a close association between severe 
constipation and psychological disorders including a past history of physical or sexual abuse. 
Addressing these problems is mandatory before considering any form of surgical intervention which 
is complex and requires a sound understanding of the underlying aetiological factors contributing to 
the patient's symptoms. 
 
SNS appears to be effective treatment for constipation but research to date has been predominantly 
confined to small low-level evidence studies with most lacking a coherent definition of constipation. 
While there may to be potential for neuromodulation in slow transit constipation, it is only 
uncommonly used in current clinical practice. This may be because of the cost of this therapy, leading 
to  reluctance by health care providers to fund the treatment in the absence of more robust data. While 
patients with evacuatory dysfunction have also benefited from treatment it is unclear which patients 
are most likely to benefit from the therapy.  Given the size of the studies and the inconsistency of the 
outcome reported to date, it would be difficult to perform any meaningful summative analysis of the 
data. 
 
Constipation is associated with a wide range of clinical features. This is important to remember when 
evaluating studies assessing treatment as often multiple outcome measures are recorded. The most 
common outcome measured in these studies is a change in the frequency of defecation.  Few studies 
describe other clinical features, such as abdominal pain, straining and the sensation of incomplete 
emptying. Only the paper by Kamm and colleagues 
95
 sought to address how the majority of these 
symptoms were affected. It is worth noting that, although many of these symptoms improved 
significantly, none completely resolved. Because of their complexity, it may be that complete 
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resolution is impossible to achieve by a single intervention. With this in mind, the aim of any 
therapeutic intervention for constipation should be to see if the patient can achieve an acceptable 
bowel function and quality of life. To this end, constipation-related symptom and quality of life 
scores, and patient based visual analogue scores (assessing overall satisfaction with bowel function) 
may be better assessments of efficacy.  
 
As with all studies of functional bowel disorders the risk of a placebo effect from those undergoing an 
operative intervention is high. The two double-blind cross over studies performed by Kenefick 
146
 and 
Dinning 
96
 demonstrate that a true clinical effect from therapy does occur and this is supported by 
outcome data that report ongoing benefit from SNS in the long-term.  
 
The success rate of PNE for constipation in adults ranges from 42% 
147
 to 73% 
95
. The reported 
success rates of PNE when used for faecal incontinence are between 74% 
107
 to 90%
55
. This would 
suggest that the rate of patients with constipation progressing from PNE to permanent stimulation is 
lower than that seen with the faecal incontinence group. However, the evidence base of SNS for 
constipation is considerably smaller than for faecal incontinence. It may be that the two or three week 
period of temporary SNS, although seemingly suitable in patients with faecal incontinence, may not 
be sufficient for patients with constipation. Govaert and colleagues 
151
 suggested that age is a 
significant predictive factor for successful PNE, in favour of younger patients whilst Carriero and 
colleagues 
152
 suggested that psychological assessment may aid the selection of patients.  
 
So far, follow up of these patients has been relatively short.  The longest duration of follow-up has 
been a median of 37 months. It is unclear whether any early improvement of constipation is 
maintained in the longer term. It is known that there is a gradual loss of efficacy over the long-term in 
some patients undergoing SNS for faecal incontinence 
158
 and it could be assumed that this may also 
occur in the constipation group. In some patients, adjustment of stimulation parameters may restore 
efficacy.  
 
With the exception of a reduction in rectal sensation urge and maximal threshold volume to balloon 
rectal distension, there does not appear to be any other consistent anorectal physiologic changes. This 
is analogous to SNS for faecal incontinence, where there are no consistent changes in physiological 
parameters 
91
 
105
. There is limited evidence that other forms of neurostimulation including 
percutaneous and transcutaneous posterior tibial nerve stimulation and acupuncture are beneficial in 
treating slow-transit constipation. It may be that the mechanism of action, as with faecal incontinence 
and urological disorders is mediated predominantly by the stimulation of afferent pathways. Kamm 
and Dinning have reported an increase in colonic motility in patients with slow transit type 
constipation. As previously stated, it is not clear from the literature whether slow colonic transit or 
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evacuatory dysfunction type constipation is likely to respond better to SNS. 
 
All of the studies have been uncontrolled with no direct comparison with any other treatment. Most 
studies were retrospective case series and can be graded as level IV scientific evidence. The 
exceptions to this are the double-blind cross-over study by Kenefick and the larger cohort studies of 
Kamm  and Govaert  which are level IIb evidence (see Table 1) 
132
.  
 
All patients had failed conservative measures such as biofeedback and medications. Although not 
explicitly mentioned, it can be assumed that mechanical causes for constipation were ruled out by the 
authors. Constipation often has a mixed aetiology and slow transit and evacuatory disorders can be 
present in the same patient to varying degrees. Surgery should only be considered in patients that have 
undergone full medical and psychosocial evaluation and conservative measures, including psychiatric 
treatment where necessary, have been exhausted. Sacral nerve stimulation allows a minimally 
invasive trial of therapy with low morbidity and in our opinion should be the first line surgical option 
for those with slow-transit constipation and/or rectal hyposensitivity. Further evidence is required to 
ascertain whether SNS is truly beneficial in those with pelvic floor dyssynergia.  
 
Based on the evidence of this limited number of studies, SNS appears to be effective treatment for 
chronic constipation. Larger clinical and cost-effectiveness studies comparing sacral nerve stimulation 
with alternative treatments are required. Better-defined measures of constipation using improved 
symptom and constipation specific quality of life scores should be used. Patients often complain of 
multiple symptoms, and frequency of defecation, although sometimes important, is not the only 
endpoint.  
 
4.2 Posterior tibial nerve stimulation for constipation 
 
Method 
A review was performed of all the evidence published on posterior tibial nerve stimulation for 
constipation.  An electronic search was performed of the Medline, Pubmed and Embase databases 
using the keywords and/ or MeSH “tibial”, “constipation”, “neuromodulation”, “stimulation”. Further 
relevant studies were identified by cross referencing from relevant articles and abstracts. Only studies 
that reported the clinical outcome of PTNS for constipation in the English language were included. 
 
Results 
One study was found which described the outcome of PTNS for constipation. Collins and colleagues 
159
 reported the outcome of 18 patients, who had undergone twelve 30 minute sessions of unilateral 
percutaneous PTNS. All had slow transit constipation, and had failed conservative therapy. This 
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included biofeedback, laxative and enema use. Statistically significant improvements were seen in the 
Wexner score 
145
 of median 18 (10-24) to 14 (7-22) (p=0.003) and in the global PAC-QOL 
160
 score of 
2.31 (1.36-3.61) to 1.43 (0.39-3.78) (p=0.008). Statistically significant improvements were also seen 
in the frequency of defecation per week of 9 (2- 48) to 16 (1-35) (p=0.048) and in the use of laxatives. 
No change in colonic motility was seen. 
 
Discussion 
These results are encouraging in a group of patients for whom further treatment is difficult. Its effect 
upon a larger group of patients, and over a longer period of time, need to be investigated. Its effect 
upon all symptoms of constipation is uncertain. As has been seen with SNS, at best there may only be 
an overall improvement rather than a complete resolution of symptoms.  
 
PTNS is significantly cheaper than SNS in the short term. However, the patient will need to attend on 
repeat occasions for percutaneous PTNS, and it is likely there will still be a need for supplementary 
laxatives and enemas. These factors may mean that the difference in cost will narrow in the medium 
to longer term. 
 
Its mechanism of action is uncertain. Collins and colleagues failed to show any improvement in 
colonic transit time, despite significant improvements in a disease severity score, disease specific 
quality of life score and in frequency of defecation. This may be explained by the fact, that many of 
the patients had co-existing evacuatory dysfunction. This may have improved, rather than the rate of 
anterograde colonic transit. The role of placebo cannot be discounted in this study. Placebo may well 
be a common confounding factor for many neuromodulatory therapies. Its effect cannot be discounted 
until large placebo controlled studies are performed. Unfortunately, there are very few of these in the 
published literature at present. 
 
 
4.3 Pudendal nerve stimulation for constipation 
 
Method 
A review was performed of all the evidence published on pudendal nerve stimulation (PNS) for 
constipation.  An electronic search was performed of the Medline, Pubmed and Embase databases 
using the keywords and/ or MeSH “pudendal”, “constipation”, “neuromodulation”, “stimulation”. 
Further relevant studies were identified by cross referencing from relevant articles and abstracts. Only 
studies that reported the clinical outcome of pudendal nerve stimulation for constipation in the 
English language were included. 
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Results 
Only one study was found on PNS for constipation, in this case for neurogenic constipation. George 
and colleagues 
161
 described eight patients with a complete cauda equina lesion and constipation, who 
had undergone PNE. After three weeks of temporary stimulation, five achieved a greater than 50% 
improvement in symptoms and underwent chronic stimulation. One month later there was an 
improvement in the frequency of defecation from 3 (0.4) to 8 (1) (p=0.11), in the sensation of 
incomplete emptying from 80% to 0% (p=0.004) and in the Cleveland clinic constipation score 
145
 of 
17 (32) to 9 (18) (p=0.03). This improvement was maintained at a mean follow up of 12 months.   
 
Discussion 
Further work is needed to investigate the effect of PNS in patients with constipation, especially in 
those with non-neurogenic disease. Assuming that PNS works by a similar mechanism of action to 
SNS, one might speculate that its effect upon constipation will be similar to that of SNS.  
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Table 1. Results of studies of sacral nerve stimulation (SNS) for constipation.  
 
Study Study Type Level of 
Evidence 
# 
Patient 
group 
Type of 
Constipation 
PNE 
No. 
Permanent 
SNS No. 
PNE 
Success 
Rate % 
Follow 
Up 
Ganio 2001 Prospective 
Uncontrolled 
IV Adult Idiopathic 10 n/a n/a 10 days 
Malouf 
2002 
Prospective  
Uncontrolled 
IV Adult Slow colonic 
transit 
8 n/a n/a 3 weeks 
Kenefick 
2002 
Prospective 
Uncontrolled 
IV Adult Idiopathic 4 4 100 6 months 
(mean) 
Kenefick 
2002 
Double-blind 
Cross-over 
IIb Adults Idiopathic n/a 2 n/a 4 weeks 
 
Humphreys 
2006 
Prospective 
Uncontrolled 
IV Children Idiopathic * 15 n/a 13 
months 
(mean) 
Holzer 
2008 
Prospective 
Uncontrolled 
IV Adult Slow colonic 
transit and 
evacuatory 
dysfunction 
19 8 42 11 
months 
(median) 
Roth 2008 Prospective 
Uncontrolled 
IV Children Idiopathic * 17 n/a 27 
months 
(median) 
Naldini 
2010 
Retrospective IV Adult Slow colonic 
transit 
15 9 60 42 
months 
(mean) 
Kamm 
2010 
Prospective 
Uncontrolled 
IIb Adult Slow colonic 
transit and 
evacuatory 
dysfunction 
62 45 73 28 
months 
(median) 
Sharma 
2011 
Retrospective IV Adult Slow colonic 
transit & 
idiopathic 
21 11 52 34 
months 
(median) 
Govaert 
2012 
 
Retrospective IIb Adult Slow colonic 
transit and 
evacuatory 
dysfunction 
117 68 58 37 
months 
(median) 
Van 
Wunnik 
2012 
Retrospective IV Children Slow colonic 
transit and 
evacuatory 
dysfunction 
13 12 92 6- 12 
months 
Knowles 
2012 
Double-
blind Cross-
over 
IIb Adult Evacuatory 
dysfunction 
13 11 85 19 
months 
(mean) 
* denotes that is unclear how many of these patients underwent PNE 
# according to the Centre for Evidence Based Medicine, University of Oxford (Group TOLoEW. The Oxford 2011 
Levels of Evidence. The Oxford Centre for Evidence Based Medicine, http:/wwwcebmnet/indexaspx?o=5653. 2011). 
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Chapter 5 
 
Double blinded randomised multicentre study to investigate the effect of stimulation parameter 
changes on sacral nerve stimulation for constipation. 
 
Introduction 
 
SNS can be effective for the treatment of constipation, but at best it can only improvement symptoms 
rather than abolish them. It is delivered typically with a pulse width of 210 µsec and a frequency of 14 
Hz. Only the amplitude and position of the electrode are routinely adjusted. The stimulation 
parameters used for SNS are those reported by Matzel et al 
45
. They are based on settings used in 
earlier reports of SNS for urinary disorders 
101
. There is a need for improvement in the efficacy of 
SNS for constipation. Maeda et al reported adverse events, including loss of efficacy, in nearly 60% 
of patients having SNS for constipation
157
. Half of them were corrected by re-programming by re-
adjustment of the position of the electrode and by the amplitude of stimulation. Dudding et al 
103
 
reported the outcome of a double blind cross over study into the effects of altered pulse width and 
frequency in 12 patients. They suggested that a higher frequency (31Hz) and a shorter pulse width 
(90µsec) may improve the efficacy of SNS for faecal incontinence. In a similar study, Duelund-
Jakobsen et al 
102
 suggested that a higher frequency of 31 Hz may improve the outcome in the same 
patient group. 
 
The aim of this study was to assess the effect of altered pulse width and frequency in patients with 
constipation who had failed to have a significant improvement from SNS. 
 
Method 
 
Ethical approval was granted by the local ethics committee (NRES Committee London- Central, ref 
11/LO/1345). Patients were recruited according to the inclusion and exclusion criteria shown in Table 
1. Failure to achieve a significant improvement in symptoms from SNS was defined as less than a 
50% improvement in the Cleveland Clinic constipation score 
145
 when compared with baseline. In an 
effort to increase the number of enrolled patients, recruitment was extended to the Royal London 
Hospital, University College Hospital London and Aarhus University Hospital, Aarhus Denmark. 
Baseline data were obtained using a three week constipation bowel diary, the Cleveland Clinic 
constipation score 
145
, the patient assessment of constipation symptoms questionnaire (PAC-SYM) 
162
 
and patient assessment of constipation quality of life questionnaire (PAC-QOL) 
160
 . A visual 
analogue scale rated the patient’s response to the question “how happy are you with the way your 
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bowels have been functioning?” on a scale of 1-100 whereby zero indicated maximal happiness and 
100 the opposite. 
 
Each patient was exposed to the parameters in each of the five test groups (Table 2). Test group 1 
used the standard SNS settings and acted as a control. The other test groups were adjusted by either 
halving or doubling the pulse width and frequency. They were based on settings used in earlier work 
102, 103
. Each patient was randomised to each test group in random order. Randomisation was 
performed using a sealed opaque envelope, drawn by the patient, which contained a randomly 
generated order of the five settings. A technician not involved in the assessment of the patient was 
responsible for adjusting the settings, rendering both patient and investigator blind to the stimulation 
groups. The amplitude was adjusted to maintain a sub sensory stimulus in the anal area or perineum. 
The position of the electrode was adjusted only if uncomfortable stimulation occurred. Patients were 
exposed to each setting for five weeks. During each of the five weeks, the first two were regarded as a 
“wash-out” period. A bowel diary was kept during the final three weeks and the remaining 
questionnaires were completed at the end of each five week period.  
 
Once the patient had passed through each of the five settings, she was asked to state which setting was 
felt to be the most efficacious.  
 
Statistical analysis 
 
Since there had been no previously published studies on the effect of altering these parameter settings 
in constipation, it was not possible to perform a sample size calculation. This was therefore a 
feasibility study in which we aimed to recruit up to 15 patients. The results were expressed as mean 
and standard deviation. A linear regression model was used to compare the outcome from each setting 
change. The Chi-squared test was used to compare the choice of preferred settings. 
 
Results 
 
Ten patients were recruited, all were female. Their characteristics are shown in Table 3. Patient 6 
became pregnant during the study and withdrew after three setting changes. The mean values of the 
outcome measures for each Test Group are shown in Figure 1 and the results of the multi-level linear 
regression model are given in Table 4. Of all the end points, only the time spent during one defecation 
showed a statistically significant difference (p=0.04), being  shortest for Test Group 3 followed by 
Test Group 4 and longest for Test Group 1 and Test Group 5. There were differences in the patient 
satisfaction, Cleveland Clinic and PAC-QOL scores, but these did not achieve statistical significance. 
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Five patients preferred Test Group 1 and two preferred Test Group 2. There was no statistically 
significant difference between these choices (p=0.08)  (Table 5). No complications were reported. 
  
Discussion 
 
The study suggests that only time spent during defecation changed significantly was related to the 
Test Groups. It is uncertain if this difference was of clinical significance, but Test Group 1 achieved 
superior albeit non-significantly different scores for almost all other outcome measures. This may 
explain why the majority of patients preferred Test Group 1. This study suggests that alteration of the 
pulse width and frequency has a limited effect on the outcome of SNS for constipation. 
 
The small number of patients studied may have affected the ability to detect significant differences 
between each setting. We were unable to recruit the desired 15 patients, largely owing to the 
unwillingness of many of those approached to commit to the time needed to complete the study. Thus 
it was only possible by collaboration with other institutions. The three week assessment period for 
each setting was necessary to obtain an accurate representation of the patient’s symptoms of which 
frequency of defaecation per week was already low and given the design, a wash-out period had to be 
included. The period of two weeks was based on earlier cross-over studies
146
. This meant that for a 
patient to progress through all settings, required she 25 weeks of data recording. Of the 10 patients 
who were recruited, none were able to commit themselves to this rigorous regime and in the one 
patient who could not, the reason was understandable.  
Deulund-Jakobsen et al 
102
 suggested that an increased frequency of stimulation may improve the 
outcome of SNS for patients with faecal incontinence, but  this did not appear to be the case in the 
present study. This may be due to the small number of patients included but also to the possibly that  
different disorders respond differently. The variability of symptoms particularly of patients with 
constipation can make assessment of the outcome very complex to assess. It may also be that the 
outcome measures used were not sensitive enough to detect a difference. There was indeed evidence 
of considerable heterogeneity among the patients, for example in prolonged colonic transit time and 
abnormalities of defecating proctography.  
Since the mechanism of action of SNS is uncertain, it is also unclear whether slow transit or 
evacuatory-predominant constipation may benefit the most from SNS. These uncertainties make 
improvements in patient selection difficult and are compounded by the difficulty in trying to achieve a 
homogeneous population for the purposes of study.  
 
Conclusion 
This pilot study suggests that alteration of pulse width and frequency did not appear to affect 
significantly the outcome of SNS for constipation. 
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Table 1. Inclusion and exclusion criteria 
 
Inclusion criteria Exclusion criteria 
Chronic SNS for constipation for at least six 
months 
New colonic or rectal pathology 
Willing to complete all assessment forms during 
study 
Surgical intervention for constipation within six 
months 
An improvement of 50% or less of the Cleveland 
Clinic constipation score from SNS 
Previous failure to comply with a trial 
Significant psychological morbidity 
Neurological disease 
Pregnancy 
 
 
 
 
Table 2. Settings in the test groups  
 
Test Group Electrodes Amplitude Frequency Pulse 
Width 
1 Optimised 
electrode settings 
Sensory Threshold 14 210 
2 Optimised 
electrode settings 
Sensory Threshold 6.9 210 
3 Optimised 
electrode settings 
Sensory Threshold 31 210 
4 Optimised 
electrode settings 
Sensory Threshold 14 90 
5 Optimised 
electrode settings 
Sensory Threshold 14 450 
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Table.3. Patient characteristics 
 
Patient  Age/ 
years 
Duration of 
constipation/ 
years 
Duration 
of SNS/ 
years 
Defecating 
proctogram  
Colonic 
transit 
time  
Cleveland 
Clinic 
score 
before 
SNS 
Percentage 
improvement 
in Cleveland 
Clinic score 
at baseline 
1 64 40 7 Small 
rectocele 
Delayed 24 50 
2 31 10 6 Perineal 
descent 
Delayed 16 44 
3 32 16 8 Normal 
 
Normal 15 27 
4 69 20 4 Small 
rectocele 
Delayed 17 0 
5 37 30 3 Small 
rectocele 
Delayed 24 4 
6 21 16 1 Normal 
 
Delayed 15 0 
7 44 
 
3 1 Normal Delayed 14 0 
8 44 
 
20 5 Normal Delayed 11 0 
9 52 
 
10 1 Normal Delayed 14 14 
10 43 11 6 Small 
rectocele 
Delayed 24 46 
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Figure 1. Mean outcome measures for each setting 
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Table 4. Multi-level linear regression analysis 
Outcome 
measure 
Test group Results* Difference 
+
 
(95% CI) 
P value# 
Mean BO/week  1 6.0 (3.7)     0 0.57 
2 5.0 (2.9) -0.8 (-2.1, 0.5)  
3 5.6 (3.1) -0.7 (-2.0, 0.6)  
4 5.6 (2.7) -0.2 (-1.5, 1.0)  
5 5.5 (3.2) -0.9 (-2.2, 0.4)  
% of defecations  
associated with 
strain 
1 41 (37)       0 0.96 
2 36 (39) -1 (-14, 13)  
3 38 (41) 4 (-9, 18)  
4 41 (43) 0 (-13, 14)  
5 37 (41) 0 (-13, 14)  
% of defecations  
associated with 
sensation of 
incomplete 
emptying 
1 61 (29)       0 0.82 
2 60 (32) -1 (-15, 13)  
3 54 (36) -3 (-18, 11)  
4 54 (31) -7 (-21, 7)  
5 56 (27) 1 (-14, 15)  
    
Time spent per 
defecation/ 
minutes 
1 9.1 (8.8)     0 0.04 
2 8.5 (6.8) -0.8 (-2.6, 1.1)  
3 6.6 (5.0) -1.6 (-3.4, 0.3)  
4 7.0 (4.8) -2.5 (-4.2, -0.7)  
5 8.0 (8.9) -0.1 (-2.0, 1.7)  
Cleveland clinic 
score/ 30 
1 13.6 (4.6)     0 0.11 
2 15.6 (4.1) 2.0 (0.2, 3.8)  
3 15.1 (4.2) 2.1 (0.2, 3.9)  
4 14.4 (3.7)  0.7 (-1.1, 2.5)  
5 
 
 
 
14.7 (5.7) 1.8 (-0.1, 3.7)  
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PAC-SYM 
score/ 30 
1 17 (9)         0 0.33 
2 22 (6) 6 (0, 12)  
3 21 (6) 4 (-2, 10)  
4 20 (11) 4 (-2, 10)  
5 26 (9) 4 (-2, 9)  
PAC-QOL 
score/ 4 
1 1.7 (1.0)     0 0.05 
2 2.1 (0.6) 0.4 (0.0, 0.9)  
3 2.1 (0.7) 0.5 (0.1, 1.0)  
4 1.8 (0.8) 0.1 (-0.3, 0.5)  
5 1.8 (1.1) 0.1 (-0.3, 0.6)  
Overall  
Satisfaction/ 100 
1 53 (35)       0 0.06 
2 38 (29) -15 (-28, -1)  
3 36 (28) -20 (-34, -6)  
4 42 (35) -11 (-25, 2)  
5 49 (36) -8 (-22, 6)  
 
*Mean (standard deviation) 
+Mean difference in outcome (after adjusting for treatment order) between each stimulation 
parameter and the first set of settings. Corresponding confidence intervals are given for each 
estimated difference.  
# P-value to indicate the significance of the overall difference in outcome between the five 
settings. 
BO = bowels open. PAC-SYM = Patient assessment of constipation-symptoms 
PAC-QOL = Patient assessment of constipation-quality of life 
 
 
Table 5. Patient preferences 
Test group Number of patients and 
their preferred group 
(%) 
p value 
1 5 (56%) 0.08 
2 2 (22%) 
3 0 (0%) 
4 1 (11%) 
5 1 (11%) 
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Chapter 6 
 
Transcutaneous stimulation over the sacrum for faecal incontinence 
 
6. 1 A pilot study of transcutaneous stimulation over the sacrum for faecal incontinence 
 
Introduction 
Sacral nerve stimulation (SNS) appears to be effective in both short and longer term, but it is 
expensive. The equipment costs around £11500. Post operative infection has been reported in three to 
10% 
104, 105
 of cases. There is also a risk of and loss of efficacy in up to 40% 
106
. 
 
Transcutaneous electrical stimulation can be used as a cheap and safe treatment for faecal 
incontinence. Stimulation of the posterior tibial nerve (PTNS) 
111
 and dorsal clitoral nerve have 
previously been described 
163
. When this study was designed, only one paper on transcutaneous 
stimulation over the sacrum (tSNS) for faecal incontinence had been reported 
87
 and a second was 
published in 2013 
88
. Both described a significant improvement in incontinence scores following 
unilateral stimulation over S3 for several hours a day. We hypothesised that a more intense treatment 
regimen might have a greater therapeutic effect. To achieve an increase in treatment intensity, the 
duration of stimulation was increased and applied to a larger area over the sacrum. The aim of this 
study was to evaluate further transcutaneous SNS (tSNS), using bilateral stimulation over the entire 
sacrum. 
 
Method 
Ethical approval was granted by the local ethics committee (NRES Committee London- Bentham, 
reference 12/LO/0011). Patients entered the study according to the inclusion and exclusion criteria 
shown in Table 1. Informed consent was obtained. They were recruited from the outpatient clinic at 
the authors’ institution. Baseline assessment of the anorectum was made by anorectal physiology 
testing and endoanal ultrasonography. A two week bowel diary was kept, which recorded the 
frequency of episodes of faecal incontinence, frequency of defecation and deferral time to defecation. 
A visual analogue scale rated on the patient response to “how happy are you with the way your bowels 
have been functioning?” was recorded. The patient placed a mark on a visual analogue scale of 0 to 
100 from with very unhappy (0) very happy (100). The Rockwood faecal incontinence quality of life 
score 
54, the St Mark’s faecal incontinence score 89 and the Short Form 36 quality of life, SF-36, score 
were also completed 
164
.  
 
tSNS was applied using a NeuroTrac ™ Continence device (Verity Medical Ltd, UK) via four 100mm 
x 50mm electrode pads. The live pads were positioned next to each other over the sacrum. The earth 
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pads were placed lateral to these (Photograph 1). Continuous stimulation at a pulse width of 210µsecs 
and a frequency of 14 Hz was used. The amplitude was set at sub sensory level. Stimulation was 
given for 12 hours every day. All patients performed tSNS at home for four weeks. They were given 
written instructions on the use of the device and a photograph demonstrating the electrode pad and 
lead position. Markings were made over the sacrum, to indicate correct pad positioning. Each kept a 
two week bowel diary for weeks three and four. The remaining questionnaires were completed at the 
end of the four week treatment.  After four weeks of tSNS the device was returned and the patients 
were followed by telephone consultation at monthly intervals. They were withdrawn the study when 
the frequency of incontinent episodes had returned to baseline level.  
 
The primary outcome was the change in frequency of incontinent episodes per week. This was 
calculated as the mean frequency of incontinent episodes from the two week bowel diary used before 
treatment and at weeks three and four of treatment. Secondary outcome measures included the ability 
to defer defecation, frequency of defecation, changes in the St Mark’s score and quality of life. 
 
Statistical Analysis 
This was a pilot study and a sample size calculation was not performed. Since the data were non-
parametric, variance was expressed by the median and the interquartile range. The Wilcoxon Rank 
test was used for comparison of paired data. Statistical analysis was performed using SPSS computer 
software (IBM, version 20). 
 
Results 
Ten patients were recruited and all completed four weeks of treatment. Patient characteristics are 
summarised in Table 2. At the end of treatment, seven achieved a greater than 50% reduction in the 
frequency of incontinent episodes, and two of these two achieved complete continence. Of the three 
who failed to achieve a ≥50% reduction, two were male. There was a statistically significant 
improvement in the median (IQR) frequency of incontinent episodes per week from 9.5 (7.5) to 3 
(7.38) (p=0.028), and in the frequency of defecations per week from 25.5 (19.5) to 14.5 (14.88) 
(p=0.007). There was a statistically significant improvement in the ability to defer defecation from 1 
(1.25) to 4.5 (4.5) minutes (p=0.017). There were statistically significant improvements in the St 
Mark’s score from 20/ 24 (5.25) to 14.5/24 (8) (p=0.012), and in the bowel habit satisfaction score, 
from 8.5 (20) to 45 (33) (p=0.008), see Table 3. There were no statistically significant changes seen in 
the quality of life measures, see Tables 4 and 5. Body mass index did not have a significant effect on 
change in frequency of incontinent episodes. After four weeks of treatment, symptoms returned to pre 
treatment levels at a median of 2 (4.5) weeks. No complications were reported, including no reports of 
skin irritation. No adverse device-related effects on daily activities were reported. 
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Discussion 
These results suggest that tSNS may be an effective treatment for faecal incontinence in the short 
term. Seven out of the ten achieved a greater than 50% improvement in the frequency of incontinent 
episodes and two became completely continent. Statistically significant improvements were seen in 
the St Mark’s incontinence score and in the frequency of incontinent episodes. The study has several 
limitations, however. The number of patients was small and the duration of treatment was short. There 
was no control group or direct comparison to another therapy. 
 
This appears to be is the third study to report the outcome of tSNS for faecal incontinence. It is the 
first to report the use of bilateral stimulation over the entire sacrum. Chew and colleagues 
87
 reported 
the outcome of seventeen patients who underwent cutaneous stimulation over S3 for two hours a day 
for three months. Statistically significant improvements were seen in the mean faecal incontinence 
severity index from 40 to 28, in the frequency of incontinent episodes per week of 19.7 (16.2) to 12.1 
(10.9) and in one domain of the Rockwood quality of life score. No assessment of change in urgency 
was made. The results from our study appear superior to those achieved by Chew and colleagues. This 
may be because a more intensive treatment regimen was used or because stimulation was applied to a 
larger area. In 2013 Leung and colleagues 
88
 reported the outcome of twenty women who had 
undergone tSNS over S3. They used a single small electrode pad, for up to eight hours a day. At a 
median follow up of 10 (5-12) months, the mean Cleveland clinic incontinence score had improved 
from 7.9 (4.2) to 4 (3.1) (p<0.0001) and the St Mark’s incontinence score from 12.7 (5.7) to 5.8 (5.6) 
(p<0.0001). These results are encouraging and the St Mark’s incontinence score, at latest follow up 
was considerably lower that obtained by our study. However, it should be noted that treatment was 
applied for a longer duration and the baseline St Mark’s score was considerably lower.  
 
The improvements in frequency of incontinent episodes, ability to defer defecation and in the St 
Mark’s score compare favourably with SNS and percutaneous PTNS. There was no significant 
improvement in quality of life measures. This may be explained by the short assessment period. It 
may be that over a longer period, the quality of life measures will reflect the improvement seen in the 
bowel diary data and St Mark’s scores. 
  
As with other forms of neuromodulation the mechanism of action of tSNS is uncertain. This is 
considered in more detail in section 6.2. Patients were given clear instruction regarding electrode pad 
placement and markings were made over the sacrum to ensure this, but it is unlikely that the pads 
were positioned correctly every time. This may have affected the results adversely, but it may also 
imply that the pads do not need to be positioned precisely over the sacrum to produce a therapeutic 
effect. 
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tSNS is cheaper than SNS, and can be used easily at home. The stimulator costs around £60 and the 
reusable electrode pads cost £4, for four weeks of daily treatment. This is cheaper than percutaneous 
PTNS, for which the stimulator costs approximately £500 and 12 disposable electrodes cost around 
£200 are required. The device used in this study is, however, not suitable for long term use. The 
electrode leads were too long and became uncomfortable, and the stimulator needed to be reactivated 
every 90 minutes. A more suitable device is required for longer use. As with PTNS
165
,  some residual 
therapeutic effect is also seen and this may  allow less intensive  stimulation for longer term 
treatment.  
 
Conclusions 
At present the evidence for tSNS is limited and consists of three small series. Further work is needed 
to evaluate this treatment, using larger numbers of patients, examined over a longer period of time. 
The placebo effect should be considered to compare tSNS to a control group and to other treatments. 
tSNS may be an effective treatment for faecal incontinence. Further work is needed to confirm this. 
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6.2 Study to assess the effect of transcutaneous sacral nerve stimulation on external anal 
sphincter activity 
 
Introduction 
The mechanism of action of both tSNS and SNS is unknown, but stimulation of the third sacral nerve 
root will cause contraction of the external anal sphincter. This is seen during SNS lead placement, and 
is used to confirm correct lead position.  It is unclear whether tSNS can cause EAS contraction. If it 
can, then one may hypothesise that tSNS has an effect on S3 and may share a similar mechanism of 
action with SNS. The aim of this study was to assess the activity of the external anal sphincter (EAS) 
during tSNS.  
 
Method 
Ethical approval was granted by the local ethics committee (NRES Committee London- Bentham, 
reference 12/LO/0011). Consecutive patients were recruited from the authors’ institution according to 
the inclusion and exclusion criteria shown in Table 6. All were due to undergo SNS electrode 
insertion for faecal incontinence under general anaesthetic. The study was performed for each patient 
during this operation. The patient was positioned prone with the buttocks strapped apart. A 30 gauge 
25 x 0.3mm electrode needle (Alpine Biomed, Denmark) was placed percutaneously into the external 
anal sphincter. A 10 x 25 mm earth plate was placed on the thigh. The electrode needle and ground 
pad were connected to an electromyography (EMG) machine (Dantec Keypoint 952, Dantec 
Dynamics UK). tSNS was applied using a NeuroTrac ™ Continence device (Verity Medical Ltd, UK) 
via four 90mm x 50mm electrode pads. The live pads were positioned next to each other over the 
sacrum and the earth pads placed laterally. Continuous stimulation over the sacrum was performed 
using a pulse width of 210µsecs, frequency of 14 Hz and amplitude of 60 mAmps. The movements of 
the buttocks and EAS were recorded and compound muscle action potentials (CMAPs) in the EAS 
were recorded. Following this, each patient underwent insertion of the SNS electrode.  
 
Results 
Five patients were recruited. Buttock contractions were seen in all during tSNS, but no visible EAS 
activity or CMAPs were observed. When the SNS electrode was inserted, however, EAS contractions 
were seen in all patients. There were no post-operative complications. 
 
Discussion 
Stimulation of the third sacral nerve root will cause EAS contraction and a sensory stimulus at the 
anus or perineum. The motor response is used to guide SNS lead placement when performed under 
general anaesthesia. The sensory response is used to guide device reprogramming during chronic 
stimulation and lead placement when performed under local anaesthesia. Fowler and colleagues 
135
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investigated this motor response in nine females with bladder dysfunction. They found a latency of 98 
(52-140) milliseconds between stimulation of S3 and sphincter CMAP. Previous work suggested that 
direct efferent stimulation of the sphincter should have a latency of between three to five 
milliseconds. The authors concluded that this delay meant that the sphincter contraction was a reflex-
mediated action from activation of ascending afferent spinal pathways, and was not due to direct 
stimulation of efferent motor fibres. The pulse width and frequency used in this study were identical 
to the settings commonly used for SNS. The stimulation amplitude of 60mAmps was adequate to 
generate buttock contractions, and more than enough for a strong sensory response in the awake 
patient. tSNS failed to generate any EAS activity suggesting that it does not activate the afferent 
pathways necessary for the reflex mediated EAS contraction. It is unlikely, therefore, that tSNS has a 
significant effect on the sacral nerve roots. This is not unexpected when one considers the thickness of 
skin, fat and bone which lie between the electrode pad and the nerve roots. tSNS may therefore only 
produce stimulation of the cutaneous nerves. If so, stimulation of the sensory cortex would occur via 
ascending sensory pathways and this might explain its observed clinical effect. SNS has been shown 
to have a modulatory effect on cortical function 
99, 100, 166
 and this is postulated to be an important 
reason for its efficacy 
90
. It may therefore be that tSNS and SNS produce a similar cortical effect, 
although it is not clear how this may influence incontinence. Various complementary therapies for 
bowel dysfunction utilise cutaneous stimulation. There are a small number published reports of 
acupuncture 
129
, reflexology 
167
 and massage 
168
 for bowel dysfunction. The application of electrical 
stimulation to another area of the body is addressed in section 6.3. 
 
Conclusions 
It is unlikely that tSNS affects the sacral nerve roots, and therefore it is unlikely to share all aspects of 
the mechanism of action of SNS.  
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6.3 Study to assess the effect of transcutaneous electrical stimulation of the anterior abdominal 
wall 
 
Introduction 
This study was limited by the absence of a control group. This meant that a placebo effect may have 
influenced the results. To address this issue, a second group of patients underwent transcutaneous 
stimulation to a different area of the body. The area chosen was the upper anterior abdominal wall. 
There were several reasons for this. This part of the body can be accessed with ease by the patient and 
is hidden by clothes. Electrical stimulation of the upper abdominal wall is not known to be a treatment 
for faecal incontinence. Importantly, patients may believe that stimulation over the abdomen may 
influence bowel dysfunction.  
 
Method  
Ethical approval was granted by an ethics committee (NRES Committee North West- Lancaster, 
reference 13/NW/0187). With the exception of electrode pad position, all aspects of the methodology 
were retained from study 6.1. The patients were instructed to place the active pads over the epigastric 
area and the ground pads were placed lateral to these. 
.  
Statistical analysis 
This was a pilot study and a sample size calculation was not performed. Since the data were non-
parametric, variance was expressed by the median and the interquartile range. The Wilcoxon Rank 
test was used for comparison of paired data. Statistical analysis was performed using SPSS computer 
software (IBM, version 20).  
 
Results 
Six patients were recruited, all were female. One patient withdrew from the study after one week due 
to a perceived lack of efficacy. This patient was withdrawn from further analysis. The characteristics 
of these patients are shown in table 7. There was no significant improvement in the frequency of 
incontinent episodes per week, frequency of defecations per week, the ability to defer defecation, the 
bowel satisfaction visual analogue scale or in the St Mark’s incontinence score, see Table 8. There 
were no significant improvements in the quality of life measures (Tables 9 and 10). The study was 
stopped because of the poor response. 
 
Discussion 
Transcutaneous stimulation of the anterior abdominal wall does not improve faecal incontinence. 
There was no significant improvement in the symptoms of incontinence or in quality of life. This 
study was intended to act as a control for the study reported in section 6.1. The inclusion and 
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exclusion criteria are the same. The treatment regimen and data collection tools are also identical. The 
failure of abdominal stimulation may suggest that the effect of tSNS is not influenced significantly by 
a placebo effect. It is unclear why a therapeutic effect can be achieved by stimulating one area of the 
body and not another. Cortical stimulation is believed to be an important reason for the efficacy of 
SNS 
90
. It may be that tSNS stimulates the necessary area of the sensory cortex, whereas abdominal 
wall stimulation does not. 
 
This study is limited. It would have been preferable to use the same cohort of patients from study 6.1, 
but most had undergone SNS by the time this study was planned. The absence of blinding and the 
experience of a positive effect from stimulation over the sacrum would also have made their 
involvement difficult. The patients in this study were waiting for SNS. With high expectations of 
sacral stimulation, they may not have viewed abdominal stimulation in the same way. This may have 
adversely influenced the results. It would have been preferable to have used a double blind cross over 
study with a sham stimulator. This will be addressed in chapter 10. 
 
 
Conclusion 
Transcutaneous stimulation of the anterior abdominal wall is not effective for faecal incontinence.  
This study suggests that tSNS may be a genuinely effective treatment.  
 
 
 
 
Table 1. Inclusion and exclusion criteria 
 
 
 
Inclusion criteria Exclusion criteria 
Age over 18 years Inability to use stimulation device 
Faecal incontinence, defined as the involuntary 
loss of solid or liquid stool, two or more times 
per week. 
Rectal prolapse 
Intact external anal sphincter on endo anal 
ultrasound 
Active inflammatory bowel disease 
Previous conservative therapy, including 
biofeedback, without symptom resolution 
Pregnancy 
Spinal injury/ neurological disorders 
Metal implant in lower back 
Previous neuromodulation 
Other implanted electrical device, such as cardiac 
pacemaker  
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Photograph 1. 
 
 
 
 
 
 
 
Table 2. Patient characteristics 
 
 
Total number 10 
Gender 8 female 
Age 49 (8.25)* years 
Type of incontinence 8 mixed, 2 urge 
Duration of symptoms 5 (2.25)* years 
BMI 29.5 (11.75)* kg/m2 
No of vaginal deliveries 1.5 (2.75)* 
Internal anal sphincter defect 3 
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Table 3. Bowel diary data, St Mark’s score and visual analogue scale 
 
 
 
 
 
 
Table 4. Rockwood FI quality of life scores 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Baseline After treatment p value 
Incontinent episodes/ 
week 
 
9.5 (7.5) 3 (7.38) 0.028 
Defecations/ week 
 
25.5 (19.5) 14.5 (14.88) 0.007 
Ability to defer 
defecation/ minutes 
1 (1.25) 4.5 (4.5) 0.017 
St Mark’s score/ 24 
 
20 (5.25) 14.5 (8) 0.012 
Visual analogue 
scale/100 
 
8.5 (20) 45 (33) 0.008 
Domain Baseline After treatment p value 
Lifestyle 2 (0.52) 2.2 (1.15) 0.62 
Coping 1.35 (0.5) 2.0 (1.10) 0.06 
Depression 2.2 (1.32) 2.7 (1.15) 0.93 
Embarrassment 1.7 (0.62) 2.3 (1.7) 0.08 
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Table 5. SF-36 quality of life scores 
 
Domain Baseline After treatment p value 
Physical functioning 32 (22.05) 29.9 (22) 0.89 
Role physical 42.1 (28.2) 35 (28.2) 0.29 
Bodily pain 37.5 (22.95) 33.6 (17.8) 0.92 
General health 34.5 (19.7) 35.9 (20.4) 0.62 
Vitality 44.3 (9.45) 46.7 (16.55) 0.62 
Social functioning 35.4 (16.3) 30.0 (19.5) 0.68 
Role emotional 34.3 (31.6) 55.3 (31.6) 0.14 
Mental health 36.8 (15.9) 41.4 (18.2) 0.40 
Physical cumulative 29.6 (28.45) 32.7 (21.9) 0.21 
Mental cumulative 40.3 (19.25) 43.1 (24.0) 0.77 
 
Table 6. Inclusion and exclusion criteria 
 
 
Inclusion criteria Exclusion criteria 
Age over 18 years Inability to use stimulation device 
Faecal incontinence, defined as the involuntary 
loss of solid or liquid stool, two or more times 
per week. 
Rectal prolapse 
Intact external anal sphincter on endo anal 
ultrasound 
Active inflammatory bowel disease 
Previous conservative therapy, including 
biofeedback, without symptom resolution 
Pregnancy 
Spinal injury/ neurological disorders 
Metal implant in lower back 
Previous neuromodulation 
Other implanted electrical device, such as cardiac 
pacemaker  
 
Table 7. Patient characteristics 
 
 
Total number 5 
Gender female 
Age 64 (24.5)* 
Type of incontinence 3 mixed, 1urge, 1 passive 
Duration of symptoms 7 (7.5)* 
BMI 25 (12)* 
No of vaginal deliveries 2 (0.5)* 
Internal anal sphincter defect 2 
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Table 8. Bowel diary data, St Mark’s score and visual analogue scale 
 
Table 9. Rockwood FI quality of life scores 
 
 
Table 10. SF-36 quality of life scores 
 
Domain Baseline After treatment p value 
Physical functioning 46.7 (15.6) 50.9 (16.7) 0.66 
Role physical 49.2 (24.7) 56.2 (28.2) 1.00 
Bodily pain 51.6 (19.7) 37.5 (27.2) 0.29 
General health 50.6 (15.7) 50.9 (22.3) 1.00 
Vitality 42.0 (17.8) 42.0 (21.4) 0.79 
Social functioning 46.3 (18.9) 57.1 (23.1) 0.26 
Role emotional 34.3 (26.3) 55.3 (31.6) 1.00 
Mental health 45.9 (14.8) 50.4 (9.25) 0.14 
Physical cumulative 53.4 (51.9) 46.0 (23.1) 0.23 
Mental cumulative 44.0 (23.1) 47.1 (16.4) 0.50 
 
*Data expressed as median (interquartile range). 
 
 Baseline After treatment p value 
Incontinent episodes/ 
week 
 
4.9 (2.75) 2 (12.3) 0.50 
Defecations/ week 
 
13.5 (14.35) 12 (7) 0.89 
Ability to defer 
defecation/ minutes 
7 (10.5) 5 (10.5) 0.85 
St Mark’s score/ 24 
 
0 (20.0) 20 (50) 0.19 
Visual analogue 
scale/100 
 
19 (1) 18 (7) 0.49 
Domain Baseline After treatment p value 
Lifestyle 2.5 (1.45) 2.7 (1.35) 1.0 
Coping 1.8 (0.9) 2.0 (1.3) 0.85 
Depression 2.3 (1.0) 2.4 (0.4) 0.71 
Embarrassment 1.3 (0.65) 1.7 (0.65) 0.10 
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Chapter 7 
Pudendal nerve stimulation for faecal incontinence  
 
Introduction 
When sacral nerve stimulation (SNS) for faecal incontinence (FI) 
45
 is evaluated on an intention to 
treat basis, around 60% of patients will experience a greater than 50% reduction of incontinent 
episodes, and 30% will become fully continent. Approximately one third of patients will not improve 
with chronic stimulation. In these further treatment is difficult and many will progress to a 
defunctioning colostomy.  
 
SNS is believed to work partly by the activation of ascending afferent sensory fibres in the sacral 
nerve roots 
135
. Stimulation is believed to modulate local reflex pathways at the spinal cord level, 
which are integral to colonic, rectal and pelvic floor function 
90
. Central effects on the sensory cortex 
and cerebral evoked potentials have also been described 
98, 99
. One limitation of sacral nerve 
stimulation is that usually only one nerve root is stimulated. The sensory outflow from the pelvic 
floor, distal bowel and anal sphincter is predominantly found in the second and third sacral nerve 
roots and in some patients may be asymmetric or at a single level 
130, 136
. SNS is most frequently 
performed at the third root  (S3) since direct stimulation of S2 can lead to adverse effects such as pain 
in the buttock, leg or foot. Absence of sensory outflow at the S3 level may explain why SNS fails to 
benefit some patients. The pudendal nerve is derived from three sacral nerve roots, S2-S4. In theory, 
greater afferent stimulation may be achieved by stimulation of this nerve than by stimulation of a 
single sacral nerve root. In some patients this might result in an improved therapeutic effect. In 
addition, as the pudendal nerve is an isolated structure at the level of the ischial spine there is less risk 
of unwanted stimulation of adjacent nerve roots. 
 
At present, only two case reports have reported the use of pudendal nerve stimulation (PNS) for non-
neurogenic FI 
140, 141
.  One paper has described its effect in 13 patients with bowel dysfunction 
secondary to complete cauda equina syndrome 
169
. PNS has been used in a small number of patients 
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with urinary voiding dysfunction and interstitial cystitis, including those who have failed to benefit 
from SNS 
137, 138
. Two cross-over studies have suggested that SNS is superior to PNS for the treatment 
of bladder dysfunction 
142, 170
. The aim of this pilot study was to assess the efficacy of PNS for FI for 
patients who have failed to respond to SNS.  
 
Method 
Ethical approval was for the study was granted by the local ethics committee (NRES Committee 
London-Harrow, reference number 05/Q0405/112). All patients provided full written consent prior to 
study entry. Patients who had previously failed to benefit from temporary or chronic sacral nerve 
stimulation were identified from a departmental database. They were recruited according to the 
inclusion and exclusion criteria shown in Table 1. Failure to improve from SNS was defined as less 
than 50% improvement in symptoms compared to baseline. Prior to PNS, patients were instructed to 
keep a baseline bowel habit diary that assessed frequency of defaecation, number of incontinent 
episodes and ability to defer defaecation. The St. Mark's incontinence Score 
89
, Rockwood faecal 
incontinence quality of life (FIQL) Score 
171
 and Short Form 36 (SF-36) Quality of Life Score 
164
 were 
also measured. Anorectal physiology testing was performed. Anal manometry was performed using 
an eight channel water-perfused catheter (Medical Measurement Systems, New Hampshire, USA). 
Anal and mid rectal electrical sensitivities were tested using a Gaeltec EMG-2 catheter (Medical 
Measurement Systems, New Hampshire, USA). Rectal sensitivity to distension was tested using a 
polyisoprene inflatable balloon (Stericom Ltd, Chesham, UK) inflated with air from a 50 ml syringe. 
 
Surgical technique 
PNS was delivered using a Medtronic model 3093 lead (Medtronic Inc, Minnesota, USA) inserted 
under general anaesthesia. This was performed using a technique reported by George and colleagues 
in 2011 
139
.  
The same surgeon (CJV) was the primary surgeon for all lead placements. The patient was placed in 
the prone position and the buttocks were strapped apart. A mark was made on the buttocks at the 
intersection of a horizontal line from the greater trochanter of the femur and a vertical line from the 
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ischial tuberosity of the pelvis. A hollow SNS foramen needle was inserted at this point. This was 
connected to an external stimulation device (Interstim test stimulator 3692, Medtronic Inc, Minnesota, 
USA). A digit was placed into the anus. The foramen needle was advanced to the ischial spine. Anal 
sphincter contraction was felt when the pudendal nerve was stimulated by the needle. A guide wire 
was inserted down the needle and the needle removed. The skin at the point of puncture was opened a 
little by a number 11 scalpel, and an introducer sheath (Interstim Model 3550-18) passed over the 
guide wire. This was advanced until sphincter contraction was felt again. The electrode lead was 
placed down the introducer (Interstim model 3093). Its positioning on the nerve was confirmed by 
sphincter contraction and by an anterior-posterior view plain radiograph of the pelvis. The lead was 
placed on the side which produced the strongest anal motor response. In patients who had an SNS 
device already in situ, the lead was removed and the PNS lead after insertion was connected directly 
to the implantable pulse generator (IPG). In those with no previous implanted SNS, the PNS lead was 
connected to an external stimulator (Interstim test stimulator 3692) inserted into the subcutaneous 
tissues of the buttock.  
 
Peripheral nerve evaluation (PNE) 
Test stimulation was performed at a subsensory level for a three week period. During this period, 
patients kept a further bowel habit diary that recorded the response of the therapy on their symptoms. 
If the fall of the frequency of incontinent episodes with stimulation was less than 50%, the patient was 
withdrawn from the study and the lead was removed under general anaesthetic. If the reduction in the 
frequency of incontinent episodes was more than 50%, the patient underwent continuous chronic                                                                       
stimulation. In patients whose PNE was satisfactory, the 3093 lead was connected under general 
anaesthetic to a pulse generator (IPG), model 3023 or model 3058 (Medtronic Inc, Minnesota, USA) 
implanted in the ipsilateral buttock. . 
 
Stimulation was set to the parameters commonly used for sacral nerve stimulation, including a pulse 
width of 210µsec and pulse frequency of 14Hz. Electrode configuration was altered so that the 
sensory stimulus was felt in the perianal area. After initial programming, the amplitude was set at a 
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sub-sensory level. Follow-up was performed at one, three and six months and then annually. At each 
follow-up the bowel habit diary, St Mark's continence score, quality of life assessment and anorectal 
physiology studies were repeated. A study flow diagram is shown in Figure 1.  
 
Statistical analysis 
Since this was a pilot study to assess the possible benefits of a new treatment, a power calculation was 
not performed. The data were continuous and distributed in a non-parametric fashion. Variance was 
expressed as median with interquartile range (IQR). Data were compared using the Wilcoxon signed 
rank test. The defecatory deferral times in minutes were expressed as categorical data and analyzed 
using the Chi-squared test. Statistical analysis was performed using SPSS computer software (IBM, 
version 20). 
 
Results 
Ten patients who had failed to respond to SNS were recruited. Their characteristics and response to 
test PNS are shown in Table 2. Five achieved a greater than 50% reduction of incontinent episodes 
and proceeded to chronic stimulation. One patient (Patient 4) withdrew from the study at six months 
owing to mental health problems. Her data were included in the analysis up to this point. Four patients 
remained in the study. The median duration of follow up was 24 (6-36) months. No complications 
were reported. The bowel diary results and St Mark’s scores for all ten patients are shown in Table 3. 
 
Of those who had had a good response to test stimulation, a significant improvement was seen in the 
frequency of incontinent episodes from a median (IQR) of 5 (18.25) per week at baseline to 2.5 (3) 
per week at latest follow-up (p=0.043). No patient achieved complete continence. There was no 
significant change in the median (IQR) frequency of defecation per day (1 (0.75) to 1.7 (1), p= 0.11) 
or in the ability to defer defecation (p= 0.89). There was a significant improvement in the St. Mark's 
incontinence score from a median (IQR) of 19 (6.0) at baseline to 16 (4.5) at latest follow-up 
(p=0.042). Three of the four patients remaining in the study had maintained a greater than 50% 
reduction of incontinent episodes at the latest median follow up 24 (6-36) months. The results for 
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these five patients are summarised in Table 4. There was no significant change in the Rockwood 
Faecal Incontinence Quality of Life Score or in the SF-36 Quality of Life Score (Tables 5 and 6). 
Anorectal physiology testing showed significant reductions in median (IQR) rectal sensation to 
distension at urge (90 (102.5) to 50 (65)) [p=0.043] and maximal volumes (140 (102.5) to 80 (92.5)) 
[p=0.042]. Anal manometry showed no significant changes, see tables 7 and 8. 
 
Discussion 
Of the ten patients selected for PNS after a failed SNS, five fulfilled the PNE criteria for chronic 
stimulation. All five seemed to respond to the treatment initially, but only three maintained a 
reduction in the frequency of incontinent episodes by more than 50% at a median follow up of 24 (3-
36) months. There was no improvement in the ability to defer defecation or in general and disease-
specific quality of life measurements. Only a third had showed improvement in their pre-PNS 
symptoms at the latest follow up, suggesting that PNS does not benefit all patients who do not 
respond to SNS. There was no significant improvement in the quality of life. No patient was made 
completely continent. These results are disappointing.  
 
Significant reductions in urgency and maximal rectal volumes were observed. However, it is unclear 
why this should have occurred. Given the improvement in incontinence, one might have expected to 
see an increase rather than a decrease in rectal volume, but the results may have been due to small 
sample size. No significant changes were observed in anal sphincter pressure recorded by manometry. 
It is unlikely that PNS has a direct motor effect upon the sphincter complex. This would be consistent 
with the lack of effect of SNS on sphincter motor function.  This study only included patients with an 
intact external anal sphincter. It is known that SNS is effective in the presence of a sphincter defect 
105
 
and further studies on PNS are required to evaluate whether it is effective in such patients. 
 
The efficacy of SNS can be improved by alteration of the stimulation parameters 
102
. The use of sub-
sensory stimulation and the stimulation parameters used in this study were the same as those used for 
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SNS. However, given the differences between the pudendal nerve and the third sacral nerve root, they 
may not be suitable and alternative settings may yield a better outcome from chronic stimulation.   
 
There is a paucity of information on the outcome of PNS for FI. The report by Matzel and colleagues 
140
 described the use of a Bion microstimulator (Advanced Bionics Corporation, CA, USA) to 
stimulate the pudendal nerve in a patient with bowel and bladder dysfunction following an extensive 
pelvic fracture.  Bock and colleagues 
141
 reported the successful use of the Interstim device 
(Medtronic Inc, Minnesota, USA)  for PNS for two patients who had failed to improve with SNS.  
George and colleagues suggested that PNS may be effective for bowel dysfunction in cauda equina 
syndrome 
169
.  
 
Only a third of patients who had failed to improve with SNS experienced any improvement with PNS. 
PNS is unlikely to benefit those who have failed SNS. This suggests that failure to respond to one 
form of neuromodulation may predict failure to respond to any form, although this would be in 
contrast to the findings of Hotouras et al who reported a good response to SNS in 14 out of 20 patients 
who had failed to improve respond to posterior tibial nerve stimulation (PTNS) 
172
 and by the results 
obtained by Peters and colleagues who reported a favourable outcome from PNS in 41 of 44 patients 
with bladder dysfunction who had failed to improve with SNS 
138
. 
 
PNS lead is more difficult than SNS lead insertion. Patients without an indwelling SNS device had to 
undergo two operations three weeks apart, including insertion of the PNS lead and connection to an 
IPG or removal in the event of no response to PNE. Both procedures were performed under general 
anaesthetic, with the patient in the prone position, but in future it should be possible to insert the 
permanent implant under local anaesthetic. PNS has particular appeal for those who already have an 
implantable pulse generator in place, since only one operation, insertion of the PNS lead, is required. 
 
The study is limited in being small, underpowered and uncontrolled, but it is not certain whether 
larger numbers would have altered its conclusion. The patients had all failed SNS and although it is 
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possible that the results would have been different if neuromodulation-naïve subjects had been 
chosen. It is unclear how effective PNS is in these patients. More work is needed to investigate the 
effect of PNS and to compare it directly with other treatments such as SNS.  
 
Conclusion 
PNS was ineffective in most patients who had failed to respond to SNS.  
 
 
 
 
 
 
 
Table 1- Inclusion and exclusion criteria 
 
 
 
 
 
Inclusion Criteria Exclusion Criteria 
Age 18-75 years Complete spinal cord injury 
Signed informed consent Congenital anorectal malformations 
Faecal incontinence, two or more episodes per 
week 
Previous rectal surgery within last 12 months, or 
24 months for cancer 
Failed previous SNS (temporary or chronic SNS) History of Inflammatory bowel disease 
Intact external anal sphincter Chronic diarrhoea 
Failed medical therapy Stoma 
Failed behavioural therapy Active perianal sepsis 
Concurrent neurological disease 
Concurrent haematological disease 
Pregnancy 
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Figure 1. Study Flow Chart 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Patients recruited for test PNS 
n= 10 
Patients failed to achieve ≥ 50% reduction in 
frequency of soiling episodes. Exited study. 
n=5. 
Patients achieved ≥ 50% reduction in 
frequency of soling episodes. 
 n=5. 
Patient declined further involvement 
in study. Exited study. 
n= 1 
Patients remaining in study at latest 
follow up. 
 n=4. 
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Table 2. Patient characteristics and response to test PNS 
 
 
 
 
 
 
# SNS= chronic sacral nerve stimulation 
*PNS= peripheral nerve evaluation 
FI= faecal incontinence 
 
 
 
 
 
 
 
Patient Age/ 
years 
Duration 
of 
symptoms/ 
years 
Type 
of FI 
Previous anal 
surgery 
Obstetric history Type of 
neuromodulation 
used previously 
Successful 
response 
to PNS 
Number 
of 
vaginal 
deliveries 
Number 
of 
obstetric 
tears 
Deliveries 
using 
instrumentation 
1 46 13 Mixed Sphincteroplasty 2 2 0 PNE* Yes 
2 69 15 Mixed Sphincteroplasty 3 0 0 PNE* Yes 
3 43 16 Mixed No 2 1 0 SNS# Yes 
4 63 11 Mixed No 4 0 1 SNS# Yes 
5 73 4 Mixed No 4 1 0 PNE* No 
6 68 15 Mixed No 2 0 1 PNE* No 
7 58 7 Mixed Sphincteroplasty 4 0 0 PNE* No 
8 63 10 Mixed No 2 0 0 SNS# Yes 
9 74 12 Mixed No 2 1 0 SNS# No 
10 61 15 Passive No 2 1 0 SNS# No 
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Table 3. Bowel diary and St Mark’s score results 
 
Patient Baseline Test PNS Chronic PNS 
FI 
/week 
Deferral 
time/ 
minutes 
St 
Mark’s 
score 
/24 
FI/week Deferral 
time/ 
minutes 
St 
Mark’s 
score 
/24 
Latest 
follow 
up/ 
months 
FI/week Deferral 
time/ 
minutes 
St 
Mark’s 
score 
/24 
1 2 <1 17 0.3 1-5 15 24 0.5 1-5 15 
2 35 1-5 24 1 >15 6 36 2.5 5-15 16 
3 5 <1 19 1.5 1-5 18 24 1.5 1-5 16 
4* 7 <1 20 1 >15 0 6 5 1 19 
5# 7 1-5 18 5 1-5 15     
6# 20 <1 22 20 <1 17     
7# 18 1-5 18 14 1-5 17     
8 3.5 1-5 15 1 <1 13 6 3 >15 13 
9# 11 1-5 16 19.5 1-5 17     
10# 9.5 15 13 16 10 17     
 
Blacked out areas indicate that the patient did not undergo chronic stimulation 
* Patient 4 withdrew from study after six months follow up 
# Patients 5, 6, 7, 9 and 10 all failed to achieve a >50% improvement in symptoms and left study 
St Mark’s score, 0 = perfect continence, 24 = severe incontinence 
FI= faecal incontinence 
PNS= peripheral nerve stimulation 
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Table 4- Bowel diary and St Mark’s score for those having chronic PNS 
 
* = St Mark's continence score (maximum 24  [severe incontinence], 0, perfect continence) 
Variance expressed as median (interquartile range) 
FI= faecal incontinence 
 
Table 5  Median (IQR) Rockwood FI QOL scores for patients having  chronic PNS 
Domain Baseline Latest follow up p value 
Lifestyle 1.9 (1.4) 2.2 (1.95) 0.42 
Coping/ Behaviour 1.4 (0.65) 1.4 (0.55) 1.0 
Depression/ Self 
perception 
2.3 (1.3) 2.1 (0.6) 0.28 
Embarrassment 1.7 (0.7) 1.3 (1.0) 0.29 
FIQOL= faecal incontinence quality of life 
Table 6- Median (IQR) SF-36 QOL score changes for patients having chronic PNS 
 
Outcome measure Baseline Most recent follow-up 
(Median 24 months) 
p-value 
FI/ week 
 
5 (18.25) 2.5 (3) 0.043 
Defecations/day 
 
1 (0.75) 1.7 (1) 0.109 
Deferral time (n) <1 minute- 3 
1-5 minutes- 2 
5-15 minutes- 0 
>15 minutes- 0 
<1 minute- 1 
1-5 minutes- 2 
5-15 minutes- 1 
>15 minutes- 1 
0.89 
St Mark's score* 
 
19 (6) 16 (4.5) 0.042 
Domain Baseline Latest follow up p value 
Physical functioning 50.9 (57.15) 55 (37.3) 0.47 
Role physical 56.2 (51.6) 50 (42.2) 0.79 
Bodily pain 55.9 (43.0) 51.6 (27.9) 0.27 
General Health 57 (33.5) 50.9 (35.7) 0.5 
Vitality 60.9 (31.6) 44.3 (34.2) 0.29 
Social functioning 57.1 (32.3) 37 (48.6) 0.85 
Role emotional 55.3 (60.5) 34.3 (60.5) 0.29 
Mental health 57.3 (39.5) 48.2 (26.2) 0.08 
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Table 7. Anorectal physiology  
 
Patient Baseline Latest follow up 
RP PS ES IS RT RU RM IAS defect on 
endoanal  
ultrasonography 
RP PS ES IS RT RU RM 
1 33 29 12 58 25 40 65 Yes 36 18 19 14 25 35 50 
2 9 43 11 44 20 90 140 Yes 12 54 21 26 25 50 125 
3 84 48 61 17 100 130 150 No 72 69 9 28 50 65 80 
4 46 70 0 45 80 180 200 No 50 39 11 57 95 150 180 
5* 24 97 20 138 30 40 70 No        
6* 12 11 0 9 30 40 50 Yes        
7* 70 30 9 40 100 150 200 No        
8 41 22 10 35 35 65 80 No 42 20 19 30 20 50 70 
9* 56 22 0 43 25 70 95 Yes        
10* 9 20 19 77 30 50 75 No        
 
Blacked out sections indicate that these patients did not undergo chronic stimulation 
* failed to achieve >50% improvement in symptoms from test PNS 
 
Key to abbreviations (normal range in brackets) 
 
RP= resting pressure cmH2O (60-160) 
PS= peak squeeze cmH2O (50-180) 
ES= 5 second endurance squeeze cmH2O (40-160) 
IS= involuntary squeeze cmH2O (50-100) 
RT= rectal threshold volume to distension ml air (20-70) 
RU= rectal urge volume to distension ml air (35-120) 
RM= rectal maximal volume to distension ml air (100-260) 
IAS= internal anal sphincter 
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Table 8- Table to show anorectal physiological parameters for patients having chronic PNS 
 
Parameter Baseline Latest follow 
up 
p value 
Resting pressure cmH2O 
 
41 (44) 42 (37) 0.49 
Peak squeeze increment 
cmH2O 
 
43 (33.5) 39 (42.5) 0.79 
Five second squeeze 
increment cmH2O 
 
11 (31.5) 19 (10) 0.5 
Involuntary squeeze 
increment cmH2O 
 
44 (25.5) 28 (23.5) 0.5 
Rectal threshold volume (air) 
mls 
 
35 (67.5) 25 (50) 0.58 
Rectal urge volume (air) mls 
 
90 (102.5) 50 (65) 0.043 
Rectal maximal volume (air) 
mls 
 
140 (102.5) 80 (92.5) 0.042 
Anal electrical sensitivity 
mAmps 
 
11.8 (6.35) 9.5 (2.75) 1.0 
Rectal electrical sensitivity 
mAmps 
 
19.4 (7.3) 23 (20.5) 0.228 
 
Data expressed as median (interquartile range) 
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Chapter 8 
 
Transcutaneous posterior tibial nerve stimulation for faecal incontinence 
  
8.1 A randomised blinded study comparing daily with twice weekly transcutaneous posterior 
tibial nerve stimulation for faecal incontinence 
 
8.1 Introduction 
Many different regimes of posterior tibial nerve stimulation (PTNS) have been reported. These range 
from once daily to once weekly treatments given over four to 12 weeks. It is unclear what the 
optimum treatment regimen should be. No published studies have attempted to determine this. The 
aim of this study was to compare the outcome of daily transcutaneous PTNS with twice weekly 
PTNS.  
 
8.1 Method 
Ethical approval was granted by the local ethics committee (NRES Committee London- Queen 
Square, reference 11/LO/1702). Patients fulfilled the inclusion and exclusion criteria shown in Table 
1.  They were recruited from the outpatient clinic at the authors’ institution. Once informed consent 
had been obtained, patients were randomised to receive once daily or twice weekly unilateral 
transcutaneous PTNS. Randomisation was performed by a third party, who had no part in the analysis 
of the results by random selection of a sealed opaque envelope which contained the group allocation. 
The primary investigator was blind to the group allocation during the study.  
 
A two-week continence diary was kept which recorded baseline symptoms prior to therapy, including 
the frequency of episodes of faecal incontinence, frequency of defaecation, deferral time to 
defaecation in minutes [urgency], the number of episodes of soiling and pad usage. Assessment was 
also obtained by a visual analogue scale (0 ‘very unhappy’; 100 ‘very happy’) based on the patient 
response to “how happy are you with the way your bowels have been functioning?” The Rockwood 
Faecal Incontinence Quality of Life score 
54
, the St Mark's Faecal continence Score 
89
 and a short form 
36 (SF-36) survey were also measured 
164
. Changes in anorectal physiology were not measured.  
 
All patients carried out the treatment at home for six weeks. They were given one to one instruction 
on PTNS, written instructions and a photograph demonstrating the position of the electrode pad and 
lead. They were also asked to use the same leg. Each patient completed a further two week continence 
diary during weeks 5 and 6. Questionnaires were completed at the end of the six week treatment. The 
PTNS device was then returned to the hospital. All patients were interviewed by telephone at one 
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month after treatment. They were withdrawn from the study when the frequency of incontinent 
episodes had returned to the baseline level. A CONSORT study flow diagram 
173
 is shown in Figure 1. 
 
PTNS was given using a NeuroTrac ™ TENS transcutaneous electrical nerve stimulator (Verity 
Medical Ltd, UK) via two 50mm x 50mm electrode pads. The live pad was placed posterior and 
superior to the medial malleolus and the ground pad was placed approximately 10cm cephalad to this, 
see photograph one. Continuous stimulation at a pulse width of 200 µsec and a frequency of 10 Hz 
was used. The amplitude was set to produce a sensory stimulus in the ipsilateral foot at an intensity 
tolerable to the patient. Stimulation was given for 30 minutes.  
 
The primary outcome measure was the frequency of faecal incontinence episodes per week. 
Secondary outcome measures included the ability to defer defecation in minutes, frequency of 
defaecation, changes in the St Mark's score and quality of life assessment. Patients were advised to 
stop any antidiarrhoeal agents, or only to use them if necessary. 
 
8.1 Statistical Analysis 
Since there were few previous studies on PTNS, it was not possible to perform a power calculation 
based on available information. The data were non-parametric and variance was therefore expressed 
by the median and inter-quartile range. The Wilcoxon Rank test was used for comparisons between 
the groups. Deferral times were analysed as categorical variables using the Sign test. Analysis was 
performed using the SPSS computer software (IBM, version 20). 
 
8.1 Results 
Thirty patients were randomised to 15 in each group. One patient failed to attend the six week follow-
up appointment and was therefore excluded from the analysis. Baseline data are shown in Table 2. No 
adverse events were reported. At six weeks three patients in the daily PTNS group had achieved 
complete continence (Table 3), while none in the twice weekly PTNS group had done so. In the daily 
group there was a significant reduction in incontinent episodes from a median of 5 (11) to 3.5 (4.3) 
episodes per week (p=0.025). In the twice weekly group there was a non-statistically significant (p= 
0.31) reduction in the number of incontinent episodes from 6.5 (5) to 3 (6.5) episodes per week. The 
percentage reduction in the frequency of incontinent episodes was a median of 60 (87) % in the daily 
group and 50 (60) % in the twice weekly group. There were no significant changes in either group in 
the weekly frequency of defecation or the ability to defer defaecation. The twice weekly group 
patients showed a significant improvement in the St Mark's score (21 (4) to 17 (7), p = 0.012), not 
seen in the daily group. The bowel satisfaction score improved significantly in each group (Table 3). 
There was improvement in the daily group but not in the twice weekly group in the domains of 
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lifestyle and embarrassment in the Rockwood FI-QOL score. (Table 4). In the SF-36 QOL assessment 
the physical domain fell in the daily group (Table 5). Body mass index and ankle circumference had 
no statistically significant effect upon the change in incontinent episodes. The patients who 
experienced improvement in the number of incontinent episodes per week returned to the baseline 
value at a median of 4 (2.75) weeks. Those in the twice weekly group who had an improvement 
returned to baseline at a median of 4 (3.5) weeks.  
 
8.1 Discussion 
To the best of our knowledge, this is the first study which has attempted to compare different 
stimulation regimens of PTNS. When paired data were compared in each group daily transcutaneous 
PTNS achieved a statistically significant reduction in episodes of faecal incontinence, whereas twice-
weekly treatment failed to do so. In the daily treatment group, improvement in continence correlated 
to a significant improvement in two domains of the Rockwood FI-QOL score and adequate patient 
satisfaction. This may suggest that daily stimulation is more effective than twice weekly. However, 
this conclusion cannot be supported by comparison of the two groups, because the study was 
insufficiently powered, although it gives useful information for the planning of  a larger randomised 
trial to investigate further the optimum regimen of PTNS. 
 
The 50% reduction in incontinent episodes in about half the patients in each group was similar to that  
reported by Govaert and colleagues 
114
, in which 59% achieved this outcome with percutaneous 
PTNS. When sacral nerve stimulation (SNS) is assessed on an intention to treat basis, about 60% of 
patients would be expected to experience a 50% or more reduction in incontinent episodes 
107
. SNS 
and percutaneous PTNS have both been shown to improve urgency, but disappointingly this was not 
seen in either group in the present study. 
 
The improvement following transcutaneous PTNS in the study was less than that obtained for 
percutaneous stimulation in a larger study 
165
, here a reduction in the frequency of incontinent 
episodes of 4 (0-30) to 0 (0-10) and 5 (0-35) to 1 (0-27) was found for patients with urge and mixed 
incontinence. Leroi and colleagues 
123
 randomised 144 patients to receive unilateral transcutaneous 
PTNS or sham stimulation in a double blinded controlled trial. They found no significant difference 
between the two treatment arms. Although our study cannot allow a direct comparison to be made 
between transcutaneous and percutaneous PTNS, one may hypothesise that unilateral transcutaneous 
PTNS, irrespective of the treatment regimen, is not as effective as percutaneous PTNS. This finding 
was supported by a recent randomised controlled study by George and colleagues 
122
. 
 
It is unclear why there was a statistically significant improvement of the St Mark's score in the twice 
weekly group and not in the daily group. Perhaps this was due to the inclusion in the St Mark's score 
89 
 
of factors resulting from learned behaviour such as pad and anti-diarrhoeal usage. Self-assessment of 
urgency is included and the patient may not readily appreciate a change in this, if they have had 
severe urgency for a long time. Thus the St Mark's score and other FI severity scoring systems may 
not be able to discern short term changes in severity. The twice weekly group were exposed to a total 
of 12 sessions of PTNS, whereas the daily group had 42. This difference may go some way to explain 
the difference in outcome observed at six weeks. 
 
Once treatment had finished the therapeutic effect lasted for about four weeks in both groups. It is 
difficult to assess this accurately since information was obtained by telephone and the patient’s 
subjective recollection. Objective assessment using continence diaries would only be able to give this 
information if maintained continuously, which would not be practical. Four weeks is similar to the 
duration of efficacy reported by others. It might be possible then to adopt a less intensive treatment, so 
called ‘top up’ treatment as described by Govaert 114 and Hotouras 165 . 
 
PTNS is cheaper than SNS and transcutaneous PTNS is cheaper than percutaneous. The stimulator 
costs approximately £50 and four reusable electrode pads £3. These would suffice for at least six 
weeks of daily treatment. The percutaneous PTNS stimulator costs £500 and the disposable electrodes 
cost £200 for 12 sessions. Percutaneous PTNS also requires the patient to attend the hospital for the 
treatment to be delivered by a trained professional. In contrast, transcutaneous PTNS can be 
performed safely by the patient at home. This may be a more suitable for those who are unable to 
attend hospital on a regular basis. 
 
8.1 Conclusion 
Transcutaneous PTNS is safe and moderately effective in FI.  It can be used from home. Daily 
stimulation achieved a significant improvement in the frequency of incontinent episodes, but twice 
weekly stimulation did not. This may mean that daily stimulation is a more effective treatment 
regimen. However, a larger study is needed to determine this question.  
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8.2 Bilateral transcutaneous posterior tibial nerve stimulation for faecal incontinence 
 
8.2 Introduction 
Neuromodulation is believed to work via stimulation of multiple afferent sensory pathways in the 
spinal cord. This has an effect on the pelvic viscera, lower gut and the sensory cortex.
90
 Bilateral 
neuromodulation may activate a greater number of afferent sensory pathways, which could lead to an 
improved therapeutic effect. In a proportion of patients the pelvis is innervated asymmetrically 
130
 and 
unilateral stimulation may therefore not achieve optimal treatment outcome depending on the site 
used for stimulation. Bilateral SNS has been described for faecal incontinence 
71
 and bladder 
dysfunction.
174
 There are no reports of bilateral PTNS in the published literature. We therefore aimed 
to assess the effect of daily bilateral transcutaneous PTNS in a prospective pilot study. A daily 
treatment regimen was used since the previous study had suggested that this may be more effective 
than twice weekly treatment. 
  
8.2 Method 
Ethical approval was granted by the local ethics committee (NRES Committee London- Dulwich, 
reference 12/LO/0589). Patients fulfilled the inclusion and exclusion criteria shown in Table 1. 
Informed consent was obtained. A two week faecal incontinence bowel diary was kept, which 
recorded the frequency of episodes of FI, frequency of defecation and deferral time to defecation. A 
visual analogue scale rated on the patient response to “how happy are you with the way your bowels 
have been functioning” was recorded. The patient placed a mark on a visual analogue scale of 0 to 
100; zero indicated that they were very unhappy and 100 indicated that they were very happy. The 
Rockwood Faecal Incontinence Quality of Life score,
54
 the St Mark’s continence Score 89 and the SF-
36 score were also recorded.
164
 The body mass index was calculated. The ankle circumference was 
also estimated, this was measured immediately above the malleoli. 
 
After receiving initial in-hospital teaching, all patients were taught to administer PTNS at home. 
Written instructions on the use of PTNS and a photograph demonstrating the electrode pad and lead 
position were also given. PTNS was performed on both ankles simultaneously for 30 minutes daily, 
for a six week period. PTNS was given using a NeuroTrac ™ Continence device (Verity Medical Ltd, 
UK) via two 50mm x 50mm electrode pads. The live pad was placed posteriorly and superiorly to the 
medial malleolus and the ground pad was placed approximately 10cm cephalad to this. Continuous 
stimulation at a pulse width of 200µsecs and a frequency of 10 Hz was used. The amplitude was set to 
produce a sensory stimulus in the ipsilateral foot at an intensity tolerable to the patient.  
 
Each patient kept a two-week bowel habit diary during the fifth and sixth week of therapy. The 
remaining questionnaires were completed at the end of the six week treatment. The PTNS devices 
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were then returned and patients were followed up by telephone consultation at one month after 
treatment had ceased. They were withdrawn from the study when the frequency of incontinent 
episodes had returned to baseline. A study flow diagram is shown in figure 2. 
 
The primary outcome measure was the change in frequency of FI episodes per week. Secondary 
outcome measures were included the ability to defer defecation measured in minutes, frequency of 
defecation, change in the St Mark’s continence score and quality of life. Patients were advised to 
abstain from anti-diarrhoeal agent use during this study. All medication use was recorded. 
 
 
8.2 Statistical Analysis 
This was a non-randomized pilot study. There were insufficient data to perform a sample size 
calculation. Since the data were non-parametric, variance was expressed by the median and the 
interquartile range. The Wilcoxon Rank test was used for comparison of paired data. Statistical 
analysis was performed using SPSS computer software (IBM, version 20). 
 
 
8.2 Results 
Twenty patients were recruited into the study. Three patients were excluded from the analysis. Two 
did not complete six weeks of treatment and failed to return at six weeks. It was not clear why this 
occurred. One patient unwittingly entered the study in early pregnancy. She suffered a spontaneous 
miscarriage during PTNS therapy. The ethics committee and study’s sponsors were notified of this 
adverse event. 
 
Seventeen patients were included in the analysis. Baseline data are shown in Table 2. There was a 
significant reduction in the frequency of FI episodes from a median (IQR) of 6 (8.25) per week at 
baseline to 2 (7.25) per week at six-weeks (p= 0.03). At six weeks, only two patients had achieved 
complete continence. Ten (59%) patients achieved a reduction of incontinent episodes per week of 
50% or more. The remaining five (29%) had less than 50% reduction of incontinent episodes. The 
median percentage reduction in frequency of incontinent episodes was 66% for the whole group.  
 
The ability to defer defecation was significantly improved from a median (IQR) of 3 (4) minutes to 5 
(8) minutes (p= 0.03). The bowel satisfaction score improved significantly from a median of 10 (25) 
to 20 (52.5) (maximum score 100; p= 0.02). There was no significant change in the St Mark’s 
continence score (Table 3). Those patients who had experienced a reduction in frequency of 
incontinent episodes returned to the baseline value at a median of 3 (1) weeks. Body mass index and 
ankle circumference had no significantly significant effect upon the change in incontinent episodes.  
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A significant improvement was seen in the lifestyle domain of the Rockwood FI-QOL Score. There 
was also a significant improvement in the general health domain of the SF-36 QOL assessment (tables 
four and five). 
 
 
8.2 Discussion 
The treatment of faecal incontinence in patients who have failed conservative therapy is difficult. 
Surgical treatments are invasive, expensive and often give uncertain results. Transcutaneous PTNS 
has the advantage that it can be performed at home by the patient after simple training. The therapy 
does not require expensive or invasive equipment. The time required to perform the treatment may be 
inconvenient, but the direct and indirect costs are likely to be considerably lower than treatments that 
require surgery or numerous visits to and from a hospital.  
 
To the best of our knowledge this is the first study that has reported the outcome of bilateral 
transcutaneous PTNS for faecal incontinence. This treatment achieved a significant short-term 
improvement in the frequency of incontinent episodes and in the ability to defer defecation. This 
study was, however, limited by small numbers and the lack of a control group. 
 
In the largest published series to date, Hotouras and colleagues 
165
 reported the outcome of 60 patients 
with mixed FI who had undergone unilateral percutaneous PTNS. They found a statistically 
significant improvement in the median (range) frequency of incontinent episodes per week from 5 (0-
35) to 1 (0-27) and in the ability to defer defecation from 1 (0-15) to 5 (0-25) minutes. When the 
outcome of SNS is assessed on an intention to treat basis, around 70% can be expected to experience a 
50% or greater reduction in the frequency of incontinent episodes.
107
 Using an arbitrary 50% 
percentage reduction in symptoms as an end-point, the results achieved by bilateral transcutaneous 
PTNS in this study are therefore comparable to those achieved by both percutaneous PTNS and by 
SNS. However it must be appreciated that in this study and in those previously published on 
percutaneous PTNS, fewer patients appear to gain full continence with PTNS compared with sacral 
nerve stimulation and in many a 50% reduction in symptoms may not be sufficient to improve quality 
of life. The reduction of incontinent episodes with SNS appears to be more pronounced than PTNS in 
those who respond to treatment by demonstrating a positive PNS leading to permanent implantation
56, 
57
. 
 
George 
122
 and Leroi 
123
 have cast doubt on the effectiveness of unilateral transcutaneous PTNS. It is 
possible that transcutaneous PTNS can only be effective when used in a bilateral fashion although a 
significant placebo response may exist. 
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Disappointingly, there was no significant improvement in the St Mark’s continence score and patient 
satisfaction scores remained low despite a reduction in the number of incontinent episodes. As only 
two patients achieved full continence this finding may reflect dissatisfaction with any level of 
incontinence even if the frequency of episodes has been reduced. In addition, learned behaviour such 
as pad use, lifestyle changes and use of anti-diarrhoeal agents may continue. Such behavioural factors 
may take a long time to change once they have become established. Thus the St Mark’s continence 
score and other measures of incontinence may be unsuitable to detect short term changes in severity.  
 
Once treatment had finished the therapeutic effect lasted for a median of three weeks. It is difficult to 
measure this accurately. Assessment was performed by telephone consultation and relied upon the 
patient’s recollection of their recent symptoms. Objective assessment using bowel diaries would only 
work if performed continuously, this would not be practical. Three weeks is similar to the duration of 
efficacy reported by others.  Govaert 
114
 and Hotouras 
165
 described a less intensive treatment regimen, 
so called “top-up” treatment. Consideration needs to be given to how such a regimen could be applied 
to bilateral transcutaneous PTNS. 
 
One patient suffered a miscarriage during PTNS. There are no reports of the use of PTNS during 
pregnancy in the published literature. A few case reports have described SNS during pregnancy.
175-178
  
All pregnancies were uneventful, except for one which resulted in an infant with a chronic motor tic 
syndrome and a pilonidal sinus and another which resulted in premature delivery. Although it is 
unlikely that PTNS was responsible for the miscarriage, the authors suggest that PTNS should not be 
used by those who are pregnant. It may be advisable that all females of child-bearing age should 
undergo a pregnancy test before PTNS. 
 
8.2 Conclusion 
Bilateral transcutaneous PTNS appears to be effective for some patients with urge and/or passive 
faecal incontinence. Further studies are required to compare the clinical outcome and cost 
effectiveness of bilateral transcutaneous PTNS with existing, more invasive treatments. 
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8.3  Predictive factors for success of transcutaneous posterior tibial nerve stimulation for faecal 
incontinence 
 
8.3 Introduction 
The studies in sections 8.1 and 8.2 suggest that transcutaneous PTNS may be effective for faecal 
incontinence. It is, however, uncertain which patients are likely to benefit the most from PTNS. 
The aim of this study was to analyse the previous two studies to see which patient or pre-treatment, 
factor had a significant effect upon the outcome. 
 
8.3 Method 
The prospectively collected data from studies 8.1 and 8.2 were analysed. The two outcome measures 
of interest included the percentage reduction in the number of incontinent episodes per week and the 
change in urgency in minutes.  
 
8.3 Statistical Analysis 
Linear regression analysis was used for both outcomes of interest. The analysis was performed in two 
stages. First the separate association between each factor and the outcome was assessed using 
univariate analysis. Any association between any variable and the outcome was then assessed by 
multivariate analysis. Due to the small sample size, only variables showing some association with the 
outcome in the univariate analysis (p value of <0.2) were included in the multivariate analysis. A 
backwards selection procedure was used to retain only the statistically significant variables. 
The percentage reduction in incontinent episodes per week was measured as a continuous scale. The 
ability to defer defecation in minutes was measured in some cases using a continuous scale and for 
others as an interval. For these patients, the midpoint of the interval was used as the deferral time.  
Patient or pre treatment factors chosen for analysis were age, gender, duration of symptoms, type of 
faecal incontinence, body mass index, ankle circumference, external and internal sphincter defect, 
PTNS regimen and pre treatment anal manometry measurements. 
 
8.3 Results 
Reduction in the number of incontinent episodes per week. 
The results of the univariate analysis into the reduction of frequency of incontinent episodes per week 
are shown in table 11. No patient factor was significantly associated with the percentage reduction in 
incontinent episodes per week. The presence of a sphincter defect came close to achieving statistical 
significance (p=0.07). The presence of either an external or internal sphincter defect was associated 
with a 68% percentage reduction in the improvement of incontinent episodes compared to patients 
without a sphincter defect. Multivariate analysis showed that a sphincter defect was not significantly 
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related to the percentage reduction of frequency of incontinent episodes when adjusted for other 
factors.  
 
Change in the ability to defer defecation (urgency). 
Univariate analysis suggested that the peak increment voluntary squeeze pressure and peak 
involuntary increment squeeze pressure were significantly associated with the ability to defer 
defecation associated with the outcome (p = 0.05 and 0.04; Table 12). Higher values of both variables 
were associated with higher deferral times. An increase in peak increment involuntary squeeze 
pressure by 10 mm Hg was associated with an increase in deferral time of 0.3 minutes, whilst an 
increase in peak increment voluntary squeeze pressure of 10 mm Hg was associated with an increase 
of 0.2 minutes in deferral time. Multivariate analysis showed that peak increment involuntary squeeze 
pressure had a significant effect on urgency (p=0.04). The effect of peak increment voluntary squeeze 
pressure was not significant once it had been adjusted for the other variables.  
 
8.3 Discussion 
The study suggests that patients with higher pre treatment voluntary and involuntary peak increment 
squeeze pressures may experience a greater improvement in urgency following transcutaneous PTNS. 
Although statistically significant, it is uncertain how clinically significant this relationship is. No other 
patient factor had a statistically significant influence on the frequency of incontinent episodes. This is 
consistent with the findings of Hotouras and colleagues 
179
, who reported the outcome among 88 
patients who had undergone percutaneous PTNS for FI. These authors attempted to see whether a 
sphincter defect and abnormal rectal sensitivity affected the outcome, assessed by the Cleveland 
Clinic incontinence score 
54
, the ability to defer defecation and the frequency of FI episodes per week. 
No statistically significant association between these factors and outcome was observed. No other 
published report has attempted to relate patient factors with outcome after PTNS for FI.  
 
Sacral nerve stimulation (SNS) has been reported more extensively. Maeda and colleagues 
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described 244 patients who had undergone peripheral nerve evaluation (PNE) to determine whether 
permanent SNS should be carried out. They were unable find a pre-procedure factor that could predict 
the outcome of the PNE. In contrast, Dudding 
181
 and Govaert 
182
 suggested that an external anal 
sphincter defect may adversely influence the outcome of SNS in 81 and 245 patients who had 
undergone PNE. This conclusion is supported by a meta-analysis of all reports of SNS for faecal 
incontinence between 1995 to 2008 
105
.  
 
The present study was limited in several ways. First patient numbers were small, secondly there was 
considerable variation in the regimen of PTNS and thirdly the follow up was short. Sphincter defects 
should be classified more precisely with regard their size and function should be reported as 
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accurately as possible. The anal manometry data are susceptible to inter-observer variability. The 
improvement in deferral time seen with higher anal sphincter pressures is small and although 
statistically significant, the clinical significance of this finding is questionable.  
 
8.3 Conclusion 
This study suggests that patients with a higher peak involuntary squeeze pressure may have a greater 
improvement in urgency from transcutaneous PTNS, but more work is needed to be sure on this point. 
 
 
 
Table 1.  Inclusion and exclusion criteria 
Inclusion Criteria Exclusion Criteria 
Signed consent form 
 
Previous congenital or acquired spinal injury, 
tumour or surgery 
 
18-80 years of age 
 
Peripheral vascular disease 
Faecal incontinence defined as at least two 
episodes per week of involuntary loss of either 
liquid or solid stool, as demonstrated by a 
baseline bowel diary 
 
Peripheral neuropathy or neurological disorder 
Previous unsuccessful biofeedback 
 
Ano-rectal surgery within the last year 
Willing and able to travel up to the 
investigational centre for the duration of the 
study. 
 
Full thickness rectal prolapse 
 
Willing and able to complete the necessary 
questionnaires and bowel diaries. 
 
Active inflammatory bowel disease 
 
No previous neuromodulation Psychological or physical inability to deal with 
the study protocol 
 
Pregnancy  or attempting to become pregnant 
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Figure 1. CONSORT Study Flow Diagram 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Assessed for eligibility (n=45) 
Excluded  (n=15 ) 
   Not meeting inclusion criteria (n=12) 
   Declined to participate (n=3 ) 
  Other reasons (n=0 ) 
Analysed  (n=14) 
 Excluded from analysis (n=1 ) 
Lost to follow-up (n=1 ) 
Discontinued intervention (n=0 ) 
Daily PTNS 
Allocated to intervention (n=15) 
 Received allocated intervention (n=15) 
 Did not receive allocated intervention (n=0 ) 
Lost to follow-up (n=0) 
Discontinued intervention (n=0) 
Twice Weekly PTNS 
Allocated to intervention (n=15) 
 Received allocated intervention (n=15 ) 
 Did not receive allocated intervention (n=0 ) 
Analysed  (n=15) 
 Excluded from analysis (n=0) 
 
Allocation 
Analysis 
Follow-Up 
Randomized (n=30) 
Enrolment 
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Phtograph 1. 
 
 
 
Table 2. Baseline characteristics of the patients 
 
 
 
 
 
 
 
 
 Daily PTNS Twice weekly PTNS 
Total  
 
14 15 
Gender 
 
F=14  
 
 
F=12  
Median age  
 
54.5 (8.5) 51 (29) 
Type of FI 
 
 
 
Urge- 5 
Passive- 4   
Mixed- 5 
 
Urge- 4 
Passive- 2 
Mixed- 9 
 
Median duration of symptoms/ 
years  
 
6 (4.13) 5 (9) 
Median BMI (kg/m
2
) 
 
25.5 (7.4) 25 (4) 
Median ankle circumference/ cm 
 
20.7 (3.63) 20.5 (1) 
Anal sphincter defect 
 
n=7 n=6 
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Table 3. Bowel diary data, St Mark’s FI score and visual analogue score results 
 
 Daily PTNS Twice weekly PTNS 
% achieved complete 
continence 
21 (n=3) 0 
% achieved a greater or 
equal to 50% reduction 
in symptoms  
57 (n=8) 53 (n=8) 
 
 
 
 
Table 4. Rockwood faecal incontinence quality of life score  
FI-QOL 
Domains 
Daily PTNS Twice weekly PTNS 
Baseline Six weeks p value Baseline Six weeks p value 
Lifestyle 
 
2.2 (1.7) 2.6 (1.65) 0.04 2.7 (1.15) 2.75 (1.35) 0.79 
Coping 
 
1.8 (0.95) 1.75 (1.35) 0.54 1.7 (1.02) 1.75 (0.78) 0.76 
Depression 
 
2.4 (1.15) 2.4 (1.10) 0.61 2.6 (1.33) 2.9 (0.92) 0.48 
Embarrassment 
 
1.7 (0.85) 2.15 (0.4) 0.04 1.85 (1.10) 1.85 (0.7) 0.60 
 
 
 
 
 Daily PTNS Twice weekly PTNS 
Baseline Six weeks p value Baseline Six weeks p value 
FI episodes / 
week 
 
5 (11.13) 3.5 (4.31) 0.025 6.5 (5) 3 (6.5) 0.31 
Defecations/ 
week 
 
10.3 (16) 13 (11.35) 0.43 13 (14) 12.5 (15) 0.125 
Deferral time/ 
minutes* (n) 
<1 min (5) 
1-5 mins (7) 
5-15 mins(1) 
>15 mins (1) 
<1min (4) 
1-5mins (6) 
5-15mins(3) 
>15mins (1) 
0.25 <1 min (7) 
1-5 mins (6) 
5-15 mins(2) 
>15 mins (0) 
<1min (3) 
1-5mins (9) 
5-15mins(3) 
>15mins (0) 
0.125 
St Mark’s FI 
Score 
 
 
18 (5.25) 18 (4.50) 0.07 21 (4) 17 (7) 0.012 
Visual analogue 
bowel 
satisfaction 
score 
10 (21) 30 (23.25) 0.01 10 (39) 30 (40) 0.004 
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Table 5.  SF-36 quality of life score  
SF-36  
Domains 
Daily PTNS Twice weekly PTNS 
Baseline Six weeks p value Baseline Six weeks p value 
Physical 
Functioning 
PF 
47.75 (20.48) 44.6 (19.95) 0.15 47.75 (15.13) 50.90 (6.20) 0.24 
Role 
Physical RP 
42.1 (21.20) 28.00 (14.10) 0.04 52.70 (15.88) 56.20 (21.20) 0.55 
Bodily Pain 
BP 
37.50 (24.35) 33.20 (23.82) 0.21 52.90 (13.10) 54.20 (16.20) 0.92 
General 
Health GH 
45.05 (15.90) 40.35 (24.35) 0.95 45.05 (12.33) 43.90 (14.00) 0.21 
Physical 
Health total 
PCS 
40.40 (20.25) 35.60 (25.72 0.29 47.75 (9.38) 48.30 (15.20) 0.75 
 
Vitality VT 
 
43.15 (28.43) 46.70 (22.48) 0.075 46.7 (14.80) 46.70 (14.20) 0.22 
Social 
Functioning 
SF 
40.85 (27.10) 32.70 (19.00) 0.089 46.30 (29.83) 46.30 (16.30) 0.72 
Role 
emotional 
RE 
50.05 (31.60) 39.55 (31.60) 0.68 55.30 (31.60) 55.30 (10.50) 0.29 
Mental 
Health MH 
42.50 (16.48) 42.50 (17.03) 0.57 47.05 (17.13) 45.90 (15.90) 0.62 
Mental 
health total 
MCS 
44.10 (27.08) 40.55 (23.42) 0.96 48.40 (24.00) 46.70 (18.70) 0.70 
 
 
Table 6. Inclusion and exclusion criteria 
Inclusion Criteria 
 
Exclusion Criteria 
Aged 18-80 years 
 
Spinal pathology, recent surgery 
Faecal incontinence defined as at least two 
episodes per week of involuntary loss of either 
liquid or solid stool as defined by a baseline 
bowel diary  
Peripheral vascular disease 
Completed biofeedback and conservative therapy 
 
Peripheral neuropathy 
No previous neuromodulation 
 
Previous anorectal surgery within the last year 
 
External rectal prolapse 
 
Active inflammatory bowel disease 
 
Pregnancy 
 
Inability to apply the device independently 
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Figure 2. 
 
 
 
 
 
 
 
Table 7. Baseline characteristics of the patients 
Total number of patients 
 
17 
Age/ years 
 
61 (24.5)* 
Gender 
 
15 female 
Duration of symptoms/ years 
 
7 (6)* 
Type of FI Mixed 9 
Urge 2 
Passive 4 
Vaginal deliveries 2 (1)* 
 
Ankle circumference/ cm 23 (2.5)* 
 
Body mass index/ kg/m
2
 27 (5)* 
 
Anal sphincter defect  
 
5 
(External anal sphincter defect 2) 
(Internal anal sphincter defect 2) 
(Combined sphincter defect 1) 
Previous anorectal surgery 3 anterior sphincteroplasties 
1 Delorme’s procedure 
 
 
Recruited patients= 20 
Patients failed to complete treatment, 
excluded from study= 3 
Patients completed treatment and included in 
analysis= 17 
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Table 8. Bowel diary data, St Mark’s FI score and visual analogue score results 
 
 
 
 
 
 
 
 
 
 
 
 
Table 9. Rockwood Faecal Incontinence Quality of Life Score 
 
Domain Baseline End of treatment p-value 
Lifestyle 
 
2.1 (0.6) 2.5 (1.6) 0.01 
Coping/ Behaviour 
 
1.3 (0.55) 1.5 (0.55) 0.07 
Depression/ Self-
perception 
21. (1.25) 2.4 (0.8) 0.47 
Embarrassment 
 
1.3 (1) 1.7 (0.7) 0.19 
 
 
 
 
 
 
 
 
 
 
 Baseline Six weeks p value 
FI episodes / week 
 
6 (8.25) 2 (7.25) 0.029 
Defecations/ week 
 
12 (7.75) 14 (8.25) 0.30 
Deferral time/ minutes  
 
3 (4) 5 (8) 0.027 
St Mark’s  Score 
 
 
20 (5) 19 (4.5) 0.23 
Visual analogue bowel satisfaction scale 
 
10 (25 20 (52.5) 0.018 
103 
 
Table 10. SF-36 Quality of Life Scores 
Domain 
 
Baseline End of treatment p-value 
Physical functioning 
 
46.7 (18.8) 46.7 (12.5) 0.59 
Role physical 
 
35 (28.2) 35 (28.2) 0.76 
Bodily pain 
 
41.8 (22.5) 51.6 (25.2) 0.17 
General health 
 
41.5 (15.7) 46.2 (14.9) 0.04 
Vitality 
 
44.3 (17.8) 44.3 (14.2) 0.52 
Social functioning 
 
40.9 (32.5) 51.7 (27.1) 0.78 
Role emotional 
 
23.7 (31.6) 44.8 (31.36) 0.44 
Mental health 
 
43.6 (23.9) 45.9 (20.5) 0.61 
Total physical score 
 
0 (.7 (16.3) 47.6 (13.3) 0.15 
Total mental score 
 
43.2 (30.4) 44.9 (21.3) 0.88 
 
Data expressed as median (interquartile range) 
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Table 11. Univariate analysis for percentage reduction in incontinent episodes per week 
 
Variable Category Coefficient (95% CI) ● P-value 
PTNS regimen Unilateral 0 0.40 
Bilateral 14 (-19, 48) 
Gender Female 0 0.81 
Male 6 (-46, 59) 
Type of faecal incontinence Urge 0 0.69 
Passive -6 (-53, 41) 
Mixed 11 (-28, 49) 
Duration of symptoms ≤ 4 years 0 0.42 
4.1 - 8 years 25 (-15, 65) 
> 8 years 8 (-33, 50) 
Body mass index kg/m2 * 
 
- 1 (-19, 21) 0.93 
Ankle circumference cm 
 
- 4 (-2, 11) 0.20 
External anal sphincter 
defect 
No 0 0.07 
Yes -32 (-67, 3) 
Internal anal sphincter 
defect 
No 0 0.07 
Yes -32 (-67, 3) 
Age/ years ** 
 
- 5 (-7, 16) 0.42 
Anal resting pressure cmH2O 
** 
- -3 (-10, 5) 0.44 
Peak voluntary squeeze 
pressure increment cmH2O 
** 
- 2 (-3, 6) 0.45 
Five second squeeze 
increment cmH2O 
** 
- 2 (-5, 9) 0.54 
Peak involuntary squeeze 
pressure increment cmH2O 
** 
- 0 (-5, 5) 0.97 
 
*   Regression coefficients given for a 5-unit increase in explanatory variable 
** Regression coefficients given for a 10-unit increase in explanatory variable 
●
 The figures reported are the regression coefficients, along with corresponding confidence intervals. 
For the variables measured on a categorical scale these represent the change in percentage reduction 
between each category and a baseline category. For variables measured on a continuous scale, these 
represent the change in percentage reduction for a one-unit increase in each variable (changes are 
reported for different unit increases where one-unit is a small amount). 
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Table 12. Univariate analysis of the ability to defer defecation 
Variable Category Coefficient (95% CI) P-value 
PTNS type Unilateral         0 0.33 
Bilateral 1.0 (-1.0, 2.9) 
Gender Female         0 0.43 
Male 1.2 (-1.9, 4.3) 
Type of FI Urge         0 0.81 
Passive 0.5 (-2.7, 3.6) 
Mixed -0.4 (-2.7, 2.0) 
Duration of symptoms ≤ 4 years         0 0.60 
4.1 - 8 years 0.9 (-2.5, 2.3) 
> 8 years -0.1 (-1.6, 3.6) 
Body mass index kg/m2 (*) 
 
- 0.0 (-1.1, 1.2) 0.94 
Ankle circumference cm 
 
- 0.3 (-0.2, 0.7) 0.21 
External anal sphincter 
defect 
No          0 0.74 
Yes -0.4 (-2.6, 1.9) 
Internal anal sphincter 
defect 
No          0 0.35 
Yes -1.0 (-3.3, 1.2) 
Age/ years (**) 
 
- 0.1 (-0.6, 0.8) 0.79 
Resting pressure cmH2O
(**) - 0.0 (-0.4, 0.5) 0.93 
Voluntary squeeze pressure 
increment cmH2O
(**) 
- 0.2 (-0.1, 0.5) 0.05 
Endurance squeeze 
increment cmH2O
(**) 
- -0.1 (-0.5, 0.3) 0.72 
Involuntary squeeze 
increment cmH2O 
(**) 
- 0.3 (0.0, 0.6) 0.04 
 
(*)   Regression coefficients given for a 5-unit increase in explanatory variable 
(**) Regression coefficients given for a 10-unit increase in explanatory variable 
The figures reported are the regression coefficients, along with corresponding confidence intervals. 
For the variables measured on a categorical scale these represent the change in deferral time between 
each category and a baseline category. For variables measured on a continuous scale, these represent 
the change in deferral time for a one-unit increase in each variable (changes are reported for different 
unit increases where one-unit is a small amount). 
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Chapter 9 
 
Conclusions 
 
The published evidence in support neuromodulation for faecal incontinence and constipation is 
generally poor. Few studies have attempted to control for placebo or compare sacral nerve stimulation 
(SNS) directly to another treatment. Most are single group series, often retrospective. Many have 
taken a greater than 50% improvement in symptoms to indicate a clinically successful outcome. This 
is too simplistic. It does not account for the wide variance seen often for each symptom. Nor does it 
reflect the impact on quality of life, which will vary from patient to patient. When analysed on an 
intention to treat basis, around 50% may achieve a significant improvement in symptoms. This means 
that a significant proportion of patients will not benefit. 
 
 The mechanism of action of these treatments is uncertain. There is no evidence to support efferent 
motor stimulation. It is likely that modulation of afferent sensory pathways and the subsequent effect 
on gut motility and the sensory cortex are responsible. The mechanism of action needs to be 
determined before any significant improvement in efficacy may be achieved. Such improvements may 
concentrate on improved patient selection, site of peripheral stimulation and stimulation technique. 
 
Adjustment of the pulse width and frequency appeared to have no real effect on the efficacy of SNS 
for constipation. This may reflect the limited improvement achieved by SNS, and complexity of 
symptoms which are usually seen. 
 
Transcutaneous stimulation of the sacrum (tSNS) appears to be effective in the short term. It is 
cheaper and less invasive than SNS. It does not appear to have precisely the same mechanism of 
action as SNS. Although promising, the technique must be investigated further. The effect of placebo 
should be addressed. The outcome of tSNS over the longer term should be measured in a larger cohort 
of patients. tSNS should be compared to alternative forms of neuromodulation, such as SNS or PTNS.  
 
Transcutaneous posterior tibial nerve stimulation (PTNS) is also a promising treatment. Like tSNS, it 
is cheap and non-invasive. It can also be self administered at home. It is likely that its optimal form of 
administration is as bilateral stimulation during an intensive initial treatment regimen. It is unclear if it 
is effective in the longer term, or how it compares with other treatments. It may find a role in patients 
who are unwilling or too unfit for SNS. 
 
Pudendal nerve stimulation (PNS) is likely to be ineffective for patients who have failed SNS, but a 
larger study may be needed to confirm this. Given the technical difficulties associated with placement 
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of the electrode and its relative poor efficacy, PNS is unlikely to replace SNS. Its only possible role 
would be as a second line treatment for those who have an SNS battery in situ. Its failure to work also 
raises questions about whether patients who have failed to respond to one form of neuromodulation 
may benefit from another. 
 
 
Future research 
 
A review of the literature in support of neuromodulation for faecal incontinence and constipation 
suggests that future research should follow certain broad approaches. These include the comparison 
with other treatments, the optimisation of treatment regimens, optimisation of different stimulation 
techniques and determination of the mechanism of action.   
 
It is unclear whether the alteration of stimulation parameters such as pulse width and frequency will 
have any significant effect on the outcome of sacral nerve stimulation for constipation, but given the 
mixed results which are often seen, it possible that a different conclusion might be reached with more 
patients. It would be interesting to assess the response of patients who have experienced each different 
setting. A difference between baseline and follow up despite using the same stimulation parameters 
may suggest a strong placebo effect. 
 
Unilateral posterior tibial nerve stimulation appears to have only limited clinical effect, as reported in 
this thesis. Leroi and colleagues 
123
 have suggested that it is little better than placebo. Despite this, 
transcutaneous stimulation of the tibial nerve is still an attractive prospect. It is cheap and non-
invasive and can be used by the patient at home. It may be that bilateral is more effective than 
unilateral stimulation, but this is unproven and requires further investigation. A large randomised 
study to compare these two techniques is needed. Its effect in the longer term should also be 
investigated. Thought should be given to the study of tibial nerve stimulation carried out at a more 
proximal level. The nerve would be of a greater diameter due to the larger number of sensory and 
motor fibres. Stimulation at this point might be more effective, assuming that neuromodulation works 
through ascending sensory nerve fibres. The tibial nerve is positioned superficially in the popliteal 
fossa and this might be a suitable place for applying stimulation using pad electrodes. 
 
Transcutaneous stimulation of the sacrum (tSNS) has shown some promise. Like transcutaneous tibial 
stimulation, it offers a cheap, non-invasive treatment which may be self-administered. It needs, 
however, to be evaluated in a larger group of patients over a longer period of time since at the 
moment it is unclear how it compares to placebo.  
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The devices used in this thesis are clearly unsuitable for long term application. The technical 
development of smaller, less intrusive, devices is needed for delivering chronic stimulation. The 
mechanism of action of tSNS is uncertain. It is likely to affect sensory pathways, perhaps in a way 
similar to sacral nerve stimulation. It may therefore be of interest to assess the effect of tSNS on the 
sensory cortex of the brain. 
 
Pudendal nerve stimulation is ineffective for patients who have failed to respond to sacral nerve 
stimulation. Its efficacy is uncertain in patients who are neuromodulation naïve. This may merit 
further investigation. Unless significant superiority is shown, the technical difficulty associated with 
performing pudendal nerve stimulation will mean that it is unlikely to compete with sacral nerve 
stimulation, 
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